India has mastered speed in everyday essentials—groceries arrive in 10 minutes, meals in under 30. Yet, when it comes to essential medicines, delays of two to three days are still the norm. For patients, that wait isn’t just inconvenient, it can be risky too. For insurers, e‑pharmacies, and healthcare platforms, it means lost conversions and low utilisation of services that were meant to improve access. This very inefficiency in India’s pharmacy delivery system led to the creation of DocPharma, a quick-commerce healthcare infrastructure startup offering 30-minute prescription medicine deliveries through a unique B2B2C model. Founded in early 2023 by Shashank Rai and Saquib Ali, and joined by Sagar Chauhan in 2025, DocPharma is not just another e-pharmacy. It positions itself as the “AWS of medicine delivery,” serving as the invisible backend for e-pharmacies, healthcare platforms, insurers, and hospitals across India. Operating in more than 12 cities—including Bengaluru, Delhi, Gurugram, Noida, Mumbai, Ghaziabad, Faridabad, Kolkata, Pune, Chennai, Hyderabad, and Patna—the startup enables its B2B partners to fulfil prescription medicine orders within 30-60 minutes, a turnaround that has significantly boosted online medicine purchases, increased insurance utilisation, and eliminated delays that historically plagued the system. Recently, DocPharma further raised the bar by launching 30-minute medicine delivery services across Delhi, Mumbai, and Bengaluru, reinforcing its commitment to faster, more reliable healthcare access in India’s busiest metros. Source: indian startup news #healthcarestartupindia #dseidehealthcarenetwork

For decades, public health in India and across the globe has largely been the domain of the state — driven by policies, programmes, and top-down interventions. While this approach has enabled major breakthroughs in disease control and population health, taking India’s life expectancy from just 35.21 years in 1950 to over 70 years in 2025, the causes of mortality and barriers to good health in New India are very different from those that our public health systems were designed to address. As the domain of public health expands from addressing communicable diseases and infections through vaccination drives to tackling the problems of lifestyle disorders and taking healthcare services to the last mile, a new public health paradigm is emerging — one that is deeply rooted in innovation. This new public health ecosystem, anchored by startups, is bringing together Government bodies, NGOs, research institutions, and communities to co-create solutions that are context-specific and scalable. In this new paradigm, public health challenges are increasingly being met with entrepreneurial energy and scalable tech-driven solutions, not just by trying to scale state capacity by increasing manpower at the grassroots level. Startups across India are stepping in to bridge gaps and make public health service delivery more efficient in key sectors like improving maternal health outcomes, enabling low-cost diagnostics, or deploying AI-powered screening tools for diseases like cancer and tuberculosis. This transformation is being actively supported by platforms like Startup India, India Accelerator, BIRAC, and other venture capital firms that are acting as ecosystem enablers that not only fund but also mentor and scale health innovations tailored to India’s unique needs. Technology is proving to be a powerful enabler for improving India’s health outcomes. Telemedicine and mobile health platforms are expanding access to care in underserved regions. AI and machine learning are revolutionising early detection and decision support. IoT and wearable devices are enhancing real-time community-level health monitoring. Drones, cold chain tech, and supply-chain innovations are improving last-mile medicine and vaccine delivery. This innovation-driven model doesn’t replace Government efforts — it complements and strengthens them to make sure the healthcare needs of over 140 crore citizens of India can be met. In many facets of public health, India has made remarkable strides over the years. It has brought down maternal mortality from 560 in 1990 to 97 per 100,000 live births today. However, the population and geographical spread of India combined with the unique and transforming healthcare needs of individuals necessitates that technology and innovation form the core of India’s public health going forward if the rate of progress is to be maintained. Today, the leading causes of death are no longer communicable diseases, they’re instead disorders like obesity, diabetes, heart disease, cancers and Alzheimer’s. Technological innovations by startups are revolutionising treatments and preventative care in all these areas where disease burden now predominantly lies. A startup called Sunfox Technologies has developed Spandan, a portable ECG device that facilitates early detection of cardiac issues at home or in clinics - and it has already helped over 30,000 users and prevented more than 10,000 heart attacks. Another startup, Fitterfly, focuses on diabetes, obesity, and metabolic health, having managed over 50,000 patients with clinically proven HbA1c reduction of up to 1.8 per cent. BeatO, a digital diabetes management platform, boasts over 1 million users and has processed more than 6 million blood glucose readings, reducing hypoglycaemic events by 52 per cent. Twin Health works on diabetes reversal and metabolic disease management, claiming over 90 per cent success among enrolled users, with deployments in both India and the US. Wellthy Therapeutics addresses diabetes, hypertension, and cardiac health, supporting over 70,000 patients while improving medication adherence by 87 per cent and halving hospitalisation risk. Aindra Systems offers point-of-care diagnostic devices for early detection of cardiac and cancer conditions, performing 5,000+ tests monthly and operating in 100+ healthcare centres in tier-2 and 3 cities. As some startups work on developing technological solutions for these new health challenges of the 21st century, others are working to solve timely diagnostics and skilled care that still continues to be a major challenge in large parts of the country, especially in rural and underserved areas. Startups like Janitri Innovations are piloting AI-powered, wearable maternal and foetal monitoring devices in primary health centres (PHCs), enabling frontline workers to detect complications in real-time, reduce delays in care, and lower out-of-pocket costs for mothers. Another startup, SpotSense, offers ReaDx and ViewDx, compact diagnostic tools that deliver lab-quality results in minutes using just a drop of saliva or blood. These tools screen for neonatal conditions like jaundice, sepsis, and congenital hypothyroidism, as well as maternal health issues such as anaemia, diabetes, and thyroid disorders. Such real-world deployments of technologies to address pressing public health issues demonstrate how innovation can enable informed, timely decisions at the last mile - where conventional systems often fall short. While it is clear that a new paradigm for public health is already taking shape in the country, it isn’t without its challenges. The success of this new paradigm requires that startups go beyond innovation for its own sake and become ethical, embedded partners in systemic change. This starts with startups understanding in depth where the challenges of public health delivery lie, and building solutions to address those challenges rather than trying to integrate technology into areas not in need of a solution. As technology becomes more critical for public health, startups would also require radical transparency in algorithms, ensuring AI tools are explainable and unbiased, particularly for vulnerable populations. Equity must also be built in from the start, with user interfaces designed for low-literacy populations, gender-sensitive features, and offline-first modes for low-resource settings. Innovation in this sector would often mean forgoing the most technologically advanced solution in favour of a combination of low-tech tools with deep-tech backends to augment, not replace, frontline workers. Startups must also build contextual intelligence, recognising that health data means different things across regions and communities — something best achieved by co-designing with local health workers and social scientists. Participatory business models that empower ASHAs or enable community ownership can increase engagement and trust. Innovations should align with existing public systems, integrating with Government processes and local community practices instead of aiming for radical disruptions that might never materialise. Finally, startups must also plan for ethical exit strategies, ensuring continuity of service and costs by integrations into existing systems once pilots end. This depth of integrity and alignment is what new public health truly needs from entrepreneurs. Source: dailypioneer #healthcarestartupindia #dseidehealthcarenetwork

Gates Foundation India released a video on July 1, spotlighting the Aaroogya AI Foundation and its work in AI-driven wellness for underserved women. Part of the Women Changemakers series, the video has garnered over 8 million views, sparking widespread public engagement with more than 40,000 likes and over 1,000 shares across Instagram, YouTube, Facebook, and LinkedIn, according to a release. The name Aaroogya comes from the Sanskrit word Arogya, which means holistic health – a state of complete well-being, free from illness in body, mind, and spirit. True to its name, Aaroogya’s model blends grassroots healthcare delivery with advanced AI, making preventive, personalised care accessible to women in low-resource settings. The five-minute video captures the foundation’s impact since its inception in 2017: training over 4,000 community health workers, screening more than 135,000 women across India and Africa, and detecting 1,759+ early-stage cases of breast cancer, PCOS, diabetes, and anemia. The Aaroogya AI Foundation was co-founded by Dr. Priyanjali Datta, a former medical student turned tech entrepreneur and product growth leader, and Dr. Dhruv Kacker, a former medical practitioner and Johns Hopkins alumnus. As the initiative grew, Shyanjali Datta, Priyanjali’s sister, joined the leadership and now serves as Co-founder and CEO. The timing of the video’s release also carried deep personal meaning: it premiered on July 1st, the birthday of co-founders Priyanjali and Shyanjali Datta’s father, Sanjit Datta, Aaroogya’s first believer and donor. The video also honours their mother Jhuma Datta’s ongoing journey with Essential Thrombocytosis, a rare blood disorder that revealed systemic gaps in early detection and access to care. As Aaroogya’s Founding Partner and first CEO, Priyanjali led the creation of its AI-powered women’s health platform and helped scale the initiative across India and Africa. She now serves as an advisor to Aaroogya and is currently the Chief Growth Officer at Omnivations (formerly Virtual Sonics Inc.), an immersive media company, where she leads product marketing and strategic partnerships. With over nine years of experience across healthcare, technology, and media, her work has been recognized and funded by institutions including the Millennium Alliance (USAID, UK-DFID, Meta, FICCI, and India’s Department of Science & Technology), Johns Hopkins Technology Ventures, HDFC SmartUp, The/Nudge Institute, Cisco, PepsiCo India, One Young World with Novartis, and the Mulago Foundation, according to the release. “Our journey with Aaroogya has always been personal,” Priyanjali shares. “My sister Shyanjali was born with a rare condition and went through some of the most complex surgeries. That experience shaped our urgency to build better systems – more compassionate, more connected. AI today isn’t just a tool, it’s a new form of intelligence. And we’re only beginning to grasp what that shift could mean for care.” As CEO, Shyanjali Datta has led the development and rollout of MyHealthline, an AI-powered platform that enables community health workers to deliver proactive care and has demonstrated a 3X social return in cost-effective health outcomes. With a background in UX research, AI system design, and product strategy, she has held roles at Spinny and served as a senior product advisor at Travlo. Her work focuses on building emotionally aware systems that are simple, accessible, and grounded in real-world needs. “Aaroogya was born from the urgency we felt during our mother’s battle with Essential Thrombocytosis – a glaring gap in research, diagnostics, and integrated care for women,” says Shyanjali Datta. “It wasn’t just about building technology, but about creating proactive, connected systems of care. In this next chapter, we’re designing AI that doesn’t just process data – it truly understands people, with ethics, empathy, privacy, and respect at its core.” As Aaroogya enters its next chapter, it stands as both a tribute and a challenge: a tribute to the families, frontline workers, and women who shaped its journey and a challenge to the systems that have long failed them. From door-to-door screenings to designing scalable AI systems, Aaroogya continues to show that when empathy meets engineering, real impact follows. The foundation is now led by the Datta sisters, with Dr. Dhruv Kacker continuing to serve as an advisor. They’ve joined forces with a cross-continental team of Indian-origin professionals based in California and India – all united by a shared mission to reimagine healthcare for women at scale. Together, they are bridging Silicon Valley innovation with India’s public health system, building solutions grounded in lived experience and reshaping how social infrastructure can serve the next billion: Anirban Ghosh, who leads product and technology at Aaroogya, is a multidisciplinary technologist working at the intersection of design, engineering, and healthcare. He has developed impactful solutions ranging from self-serve clinics at Forward to infant care devices at GE Healthcare, all focused on expanding access to quality care. His ventures – including a chronic care platform launched at Harvard – reflect a strong commitment to health equity and last-mile innovation. Medha Jaishankar, President of Omnivations (formerly Virtual Sonics Inc.), joins Aaroogya’s advisory board with a deep commitment to human-centered innovation, storytelling, and global impact. A former BBC camera operator and producer, she is an award-winning filmmaker and media technologist who has led large-scale partnerships with companies including Sony and Safran. A member of the Pacific Council on International Policy, Medha also brings personal insight as someone navigating endometriosis, PCOS, and Hashimoto’s. Neha Goel, a former Senior AI Engineer at Microsoft, brings over 17 years of experience in responsible AI, enterprise healthcare systems, and global deployment. She has led OpenAI and LLM strategy for Fortune 500 clients, served on healthtech startup boards, and currently mentors early-stage ventures as an Expert Mentor for Microsoft for Startups. Purva Pruthi Ghosh, a machine learning researcher and AI resident at Google Labs, holds a PhD from UMass Amherst. Her work in compositional reasoning, causal AI, and modular architectures adds deep research rigor and long-term vision to Aaroogya’s AI development roadmap. Source: thenewsmill #healthcarestartupindia #dseidehealthcarenetwork

In a strategic move to fortify India's biomanufacturing landscape, Danaher India, part of the global science and technology giant Danaher Corporation, has entered into a partnership with the Translational Health Science and Technology Institute (THSTI). The collaboration, revealed during THSTI’s 16th Foundation Day celebrations and the 2nd Industry Business Meet, is aimed at accelerating innovation in life sciences, biotechnology, and healthcare. The initiative focuses on capability building and infrastructure development, with the goal of supporting researchers, biotech startups, and manufacturers working on critical health challenges. The event witnessed participation from leading scientists, industry stakeholders, and policymakers. “At Danaher, we are committed to advancing science and improving lives. Strengthening India’s biomanufacturing capabilities is a transformative goal that demands deep, collaborative partnerships across the entire innovation ecosystem,” said Sanjay Murdeshwar, Regional President, Danaher India. Prof. Ganesan Karthikeyan, Executive Director of THSTI, welcomed the partnership, stating, “This collaboration with Danaher India is a significant step toward making India a global hub for affordable healthcare products. By leveraging Danaher’s technological leadership and THSTI’s translational research strengths, we aim to empower Indian innovators with the tools and infrastructure needed to bring breakthrough healthcare solutions to market faster.” Key focus areas of the partnership include: Joint training programmes for researchers and startups Co-development opportunities in life sciences Expanded access to cutting-edge technologies for biotherapeutics This collaboration marks a pivotal step in enhancing India’s ability to respond to emerging health needs while positioning itself as a leader in the global biomanufacturing arena. Source: bwdisrupt #healthcarestartupindia #dseidehealthcareindia

Insurance tech platform, Plum commits a Rs 200 crore (USD 25 million) investment to expand its healthcare vertical. As part of this shift, the company has appointed Prayat Shah, former co-founder of Wellthy Therapeutics, as Head of Healthcare. The company also plans to increase its healthcare team fivefold. Plum has launched ‘Plum Health Checkups’, an at-home screening service that includes over 200 biomarkers, AI-generated health reports, and teleconsultation follow-ups. The service is available across 4,000+ locations with home sample collection and real-time tracking. The company reported over 1 lakh telehealth consultations in 2024, including 20 per cent related to mental health. Plum cited internal data showing limited adoption of preventive health measures, only 20 per cent of companies offer check-ups, and fewer than 40 per cent of employees use them. The company stated that its aim is to move employee healthcare from reactive to preventive. It plans to integrate services such as consultations, diagnostics, and risk assessments into a single offering. Plum currently serves more than 6,000 companies and 6 lakh employees across India. Source: bwdisrupt #healthcarestartupindia #dseidehealthcarenetwork

Clinics on Cloud, a health tech company founded by Pune-based couple Abhay and Manashrri Agarwal, has announced the large-scale deployment of its AI-powered Health ATMs across underserved regions. A health ATM combines a physical kiosk with telemedicine and point-of-care devices designed to provide accessible and affordable healthcare. Abhay Agarwal, founder and CEO of Clinics on Cloud, spoke about the urgent need to modernise rural healthcare. “India’s rural population often lacks access to timely diagnostic services, which delays treatment and increases health risks. Our Health ATM concept is designed to bridge this critical gap—bringing over 65 rapid diagnostic tests to the doorsteps of rural citizens,” he said. This comprehensive preventive health screening can be done in 10 minutes and can also help reduce medical costs, Agarwal added. These AI-enabled Health ATMs can perform a wide array of health checks—from routine vitals and blood pressure to advanced screenings for diabetes, cardiac conditions, hemoglobin levels, and infectious diseases like dengue, malaria, Covid-19, and HIV. The tests include a general health check-up (body mass index, pulse, SPO2, body temperature, muscle mass, bone mass and so on), urine rapid test, ear and eye tests, pulmonary function tests among others. Reports are generated instantly, ensuring timely medical consultation through telemedicine, even in remote regions. Manashrri Agarwal, co-founder and Managing Director of Clinics on Cloud, added that the goal is to make preventive healthcare accessible, affordable, and accurate for every Indian—regardless of location. “These Health ATMs have an accuracy rate of over 95% and operate at a fraction of the cost of traditional labs,” she said. In a unique collaboration with distribution partner DynaBlaze, Clinics on Cloud has engineered the Health ATMs to function without the need for electricity or internet, making them perfectly suited for deployment in electricity-deficient rural zones. The machines are available through EMI and rental options, also creating local employment opportunities by training health operators in villages. Source: Indian Express #healthcarestartupfunding #dseidehealthcarenetwork

AI-first startups in APAC are transforming core industries by redefining business models, boosting efficiency, and opening new market opportunities. Across the Asia-Pacific region, a new wave of AI-first startups is altering how industries operate. Built with artificial intelligence at their core, these ventures are layering AI onto legacy systems and creating entirely new ways to deliver value. Unlike traditional firms tied to high overheads and rigid models, AI-native companies operate with leaner structures, data-driven insights, and scalable platforms. These startups are transforming existing workflows and expanding access to previously underserved markets, from remote diagnostics to micro-lending. In 2024, global AI startups attracted approximately US$131.5 billion in venture capital investments, a significant increase from previous years. While specific figures for the Asia-Pacific region are not readily available, the region has seen a notable uptick in AI startup funding, reflecting growing investor interest. This signals a regional realignment, where startup ecosystems in countries like Singapore, India, China, and South Korea are becoming drivers of business model reinvention. AI in healthcare is accelerating diagnosis and democratising access AI startups are transforming how healthcare diagnostics and treatments are developed and delivered. Their focus is on improving accuracy and increasing reach and speed in ways that traditional providers struggle to match. For instance, India’s Qure.ai uses deep learning to analyse chest scans and detect conditions such as tuberculosis and lung nodules. Its AI can interpret medical images within seconds, enabling fast triage in hospitals and rural clinics alike. The company operates on a diagnostics-as-a-service model, charging healthcare providers per scan. With over 90 countries using its tools and a recent US$65 million Series D round, Qure.ai is expanding partnerships with global pharma firms such as AstraZeneca. Source: Techedt #healthcarestartupindia #dseidehealthcarenetwork

Siemens Healthineers, a leading medtech company with a legacy of over 125 years, is always on the search for new technological breakthroughs in healthcare. In Bengaluru, it has found the perfect match for driving innovation. Bengaluru is one of the four global innovation hubs for Siemens Healthineers, with its Bengaluru global capability centre (GCC) equipped with competencies in areas such as data analytics, artificial intelligence, immersive technologies like augmented and virtual reality, user experience, and cybersecurity. In addition, Siemens Healthineers is also actively partnering with deeptech startups in India, especially those from the healthcare sector. This collaboration is largely thriving on the growing convergence between medtech and emerging technologies like GenAI, digital twins, robotics, sensors, and immersive technologies. The idea is to harness the relationship to the fullest. Indian deeptech startups have the specialised expertise in emerging technologies, and Siemens Healthineers brings the much-needed experience as well as reach, making such partnerships complementary. This collaboration has already brought in certain breakthrough ideas and fresh thinking to the ecosystem. In an e-mail interview with Enterprise Story, Kalavathi GV, Executive Director and Head of Global Development Center, Siemens Healthineers, said, “Working closely with the startup ecosystem is a key part of how we envision advancing healthcare through new technologies and business models. “ Source: Your Story #healthcarestartupindia #dseidehealthcarenetwork

The number of Indian startups selected by Silicon Valley’s famed accelerator Y Combinator (YC) has plummeted to just four in 2024 from 66 in 2021, marking a sharp decline in participation from one of its most active international markets in recent years, according to information sourced from YC’s website. This comes at a time when Indian founders are increasingly opting to remain domiciled locally amid evolving regulatory dynamics and healthy prospects of listing on the domestic stock exchanges. According to industry executives and founders from YC’s India portfolio, the decline is driven by multiple factors, including YC’s requirement for accepted startups to set up a parent entity in the US, Canada, Singapore, or the Cayman Islands, even if they are originally incorporated elsewhere. There is also a growing trend of startups shifting their holding entities to India in preparation for domestic IPOs. This reverse flipping entails paying hefty taxes in the US. Among startups that were part of YC, IPO-bound stock broking platform Groww paid around $160 million in taxes as it flipped its parent entity from the US to India last year, while Razorpay is estimated to have incurred a tax outgo of around $200 million and Meesho is expected to pay around $280-300 million. Another reason flagged by founders and investors is that YC is increasingly focusing on deeptech and AI-first startups, many of which require cutting-edge research and are often built around US-based technical talent. This evolving thesis has made it harder for early-stage Indian companies to gain admission, they said. “YC has pulled back a little from India because they were not getting the quality they wanted at the volumes they were seeing in India. There are still a lot of Indian companies which go and apply, but they don’t have a separate India strategy now, which is why we are seeing a smaller number of companies selected,” an investor said on the condition of anonymity. Under the leadership of OpenAI founder Sam Altman, during the 2014-19 period, YC began to double down on India intakes. This was the time when startups like Meesho, Groww, Razorpay became a part of the YC batches. Other high-profile companies like quick commerce platform Zepto came on board in 2021. Source: Economic Times #healthcarestartupindia #ycombinator #dseidehealthcarenetwork

Guttify, the premium gut health startup by Lifechart, is in advanced negotiations with leading venture capital firms to secure Rs 20 crore in its upcoming funding round. The company, recognised for its “Diagnosis-First” approach to gut wellness, has rapidly gained traction in the consumer healthcare space. Sources indicate that 60 per cent of the round is expected to close with a prominent VC specialising in healthcare and consumer investments. Guttify’s credibility is further bolstered by the recent addition of Prashant Pitti (Founder, EaseMyTrip & Optimio) as a strategic advisor and investor, along with support from UNICHEM Laboratories' family office and existing backers. In May 2025, the startup raised USD 360,000 in extended seed funding, bringing its total funding to over USD 1 million. The fresh capital will fuel Guttify’s expansion of its diagnosis-first, at-home gut wellness solutions across urban and semi-urban India. "Our mission is to solve chronic gut health issues from the core using science and diagnostics. The new funding will help us scale product development, distribution, and research for personalised gut care," said Mukul Shah, co-founder at Guttify. As part of its innovation pipeline, Guttify is set to launch India’s first RNA gene-based DIY gut testing kits, promising results within 24 hours. This affordable, at-home solution aims to democratise gut health testing, enabling individuals to better understand and manage their digestive health without invasive procedures or clinic visits. Source: bwhealthcareworld #healthcarestartupindia #dseidehealthcarenetwork

Suraksha Diagnostic Limited (Suraksha Daignostic), one of the leading diagnostics chains in Eastern India has launched one of the largest and a state-of-the-art genomics labs in Eastern India. The launch was graced by Prof. Sukumar Mukherjee, a distinguished rheumatologist with more than 35 years of extensive experience in the field and a mentor at Suraksha Diagnostic. The global genetic testing market is valued at USD 38.77 billion (2024) and is projected to reach US$ 186.64 billion by the year 2035 (CAGR: 22.5%). In a landmark move, Suraksha Diagnostic has invested ₹22 crores in establishing its Genomics Lab. An additional Rs. 46 crore investment is planned over the next 24 months to establish one of Asia's most advanced Genomics Laboratories. This initiative is a significant leap forward for West Bengal, Eastern & North-Eastern India, and India's future in precision diagnostics. This Lab is equipped with Cytogenetics, Microarray Technology, Sanger Sequencing, Multiple Next-Generation Sequencers (NGS). Together, these technologies enable the full spectrum of advanced genetic testing, offering predictive, preventive, and personalized care. Speaking on the launch of the genomics lab, Dr. Somnath Chatterjee, Chairman & Joint Managing Director, Suraksha Diagnostic, said: "A huge transformation is sweeping across medicine today. At the heart of this revolution lies Genomics - unlocking the secrets of the Human Genome, enabling early diagnosis, predictive analytics, and personalized treatments. From Fetal Medicine to Oncology and Rare Diseases, genomic science is rewriting the future of healthcare. Suraksha Diagnostic is proud to be at the forefront of this revolution." Ritu Mittal, Joint Managing Director & CEO, Suraksha Diagnostic, also emphasized the lab's role in making genomic diagnostics a critical part of healthcare decision- making in Eastern India and shared: "We provide end-to-end solution for prenatal genetics, offering comprehensive testing facilities. We aim to be a premium, aspirational choice for clinicians and families seeking the highest standards in fetal, reproductive, paediatric and onco-genetics without the need to send samples out of the region or compromise on quality Source: Indian Pharma Post #healthcarstartupindia #dseidehealthcarenetwork

Mumbai-based fertility health-tech startup Luma Fertility has raised $4 million in seed funding, led by Peak XV’s Surge, with participation from Ameera Shah (Metropolis Healthcare) and Vijay Taparia (B2V Ventures). The funding will help Luma expand its footprint in Mumbai and later scale into subsequent cities over the next two years. Ameera Shah, promoter and executive chairperson of Metropolis Healthcare, said, “Fertility care in India is at an inflection point. Demand is growing rapidly, but the system is deeply fragmented and outdated. Patients are forced to navigate a maze of clinics, labs, and specialists with little coordination or support.” Founded by Neha K. Motwani, Luma Fertility’s 6,000-square-foot facility houses a lab and offers comprehensive in-house fertility procedures. Its services include IVF, egg and embryo freezing, fertility assessments, and pre-conception consultations. Luma also offers at-home semen analysis, personalised reports, and a range of holistic services—such as nutrition guidance, acupuncture, IV drips, and one-on-one sessions—to support both physical and emotional well-being and improve overall outcomes. Luma is the first IVF clinic to launch an integrated app, allowing patients to track their treatment, access reports, and stay informed. Its AI-enabled tool, LumaAI, offers 24/7, jargon-free support on everything from cycle timelines to medication guidance. The global fertility services market is projected to reach $53 billion by 2030, driven by factors such as delayed parenthood, increasing age-related infertility, and declining global fertility rates. In India, the total fertility rate is at a historic low, declining from 2.1 to 1.9 births per woman. Over 33 million couples in the country face fertility challenges, with IVF cycles expected to grow from 320,000 in 2024 to 550,000 by 2028. As India’s economy evolves and per capita income rises, there is significant latent demand for transparent, patient-centric, and tech-enabled fertility solutions, including egg and embryo freezing. Source: Business Standard #healthtechstartup #dseidehealthcarenetwork

GTT Data Solutions has unveiled GAIN (GTT Data AI Accelerator Network)—a strategic initiative designed to accelerate India’s AI startup ecosystem by fostering innovation, collaboration, and funding support. The accelerator will provide mentorship, business advisory services, go‑to‑market assistance, and access to strategic partnerships across sectors such as healthcare, pharmaceuticals, engineering, retail, legal, and real estate  GAIN aims to support more than 100 AI startups over the next six months, with potential investments facilitated through Sangli Miraj Commercial Ventures The launch event in Pune featured 22 AI companies and 45 founders showcasing innovations centered on intelligent automation, advanced healthcare AI (including medical imaging), and vision AI focused on visual data processing GTT Data’s President, Srikumar Kumar, emphasized a philosophy of “dual intelligence”—where AI complements human expertise—and emphasized that AI must uplift humans, not replace them. He added, “GAIN is our commitment to making India a formidable, collaborative force in the global AI movement”  This initiative addresses critical challenges facing India's AI startup landscape, which now hosts over 4,500 ventures, nearly 40% of which were founded in the past three years. With a steep failure rate—90% don't survive, and 70% shut down within a decade—GAIN seeks to foster collaboration over competition and support startups in building scalable, sustainable business models  Why this matters: Bridging the gap between early‑stage AI innovation and real‑world adoption. Enhancing survival prospects for startups by offering funding access, mentorship, and market entry support. Targeting critical AI verticals like healthcare imaging and cognitive automation—key growth drivers. Backing from established players, ensuring credibility and expanded ecosystem connectivity. With GAIN, GTT Data is taking a proactive step in nurturing India’s deep‑tech future, reinforcing its broader ambition to scale its Dual Intelligence strategy through acquisitions, talent development, and expanded operations across tier‑2 and tier‑3 cities  Source: Times of India #healthcarestartupindia #dseidehealthcarenetwork

As healthcare costs continue to rise and insurance penetration remains limited—currently covering only about 36% of the population—millions of Indians are left financially vulnerable during medical emergencies. Recognising this systemic gap, fintech innovator CarePay has launched Careena – an AI-powered healthcare EMI platform designed to make medical financing more seamless, accessible, and patient-centric across India. CarePay’s newly launched platform offers instant, no-cost EMI approvals up to ₹10 lakhs for a wide spectrum of healthcare needs, including surgeries, diagnostics, chronic disease management, and preventive health services. At the heart of this digital transformation is Careena (CARE Engagement Assistant), an intelligent AI-based assistant developed to guide patients through the financing process in real-time. Built with user-centricity in mind, Careena evaluates key data points such as employment status, educational background, and income levels to offer instant eligibility checks and approval decisions within minutes—a process that traditionally took days. “Our goal is to dismantle the financial barriers preventing timely medical intervention. Careena is more than just a digital tool—it’s a healthcare financing companion that ensures timely access to quality care without the financial stress,” said Gaurav Gupta, CEO of CarePay. Key features of the platform include: 0% EMI options, where partnering hospitals absorb the interest cost to enhance patient acquisition. AI-based risk assessment that ensures accurate and swift loan approvals. Mobile-first design for easy access across all devices and seamless integration with hospital management systems. End-to-end encryption and regulatory compliance to uphold data privacy and security. The company has already gained significant traction in the healthcare ecosystem, with strategic alliances across 550+ wellness centres, 1,500+ clinics, and over 30 leading hospitals. CarePay has also collaborated with five multinational healthcare firms and 25 chronic care facilities to broaden the reach of its innovative financial solutions. Source: e.health #healthcarestartupinindia #dseidehealthcarenetwork

Over the past week, you might’ve noticed something interesting. Shares of India’s diagnostic companies have taken a bit of a tumble. Stocks like Suraksha Diagnostic, Krsnaa Diagnostics, Thyrocare Technologies, Metropolis and Dr. Lal PathLabs slipped by up to 2%, even as the broader market moved in the opposite direction. And you’ve probably guessed what’s spooked investors this time. But if you haven’t, well, Amazon just threw its hat into India’s diagnostics ring. It’s now offering at-home test collections, digital reports and bundled health services across six cities covering 450 pincodes. The buzz is that it could shake things up in a big way. But here’s the thing. This isn’t Amazon’s first rodeo in Indian healthcare. It’s already dipped its toes into e-pharmacies and online consultations. Sure, those services are still around, but let’s be honest. They haven’t exactly set the world on fire. It’s more of a work-in-progress than a roaring success. So why is Amazon doubling down and adding new pieces to its healthcare puzzle when it hasn’t really cracked the code yet? Well, the simplest answer is that it already had e-pharmacies. But to figure out what to sell, it needed to know why people were buying medicines in the first place. That’s where online consultations came in handy. People could talk to doctors from home, get prescriptions and Amazon could plug into that system — supplying medicines and figuring out which pharmacy partners to work with in each region. But what happens when a doctor suggests a blood test? People typically head to the nearest lab or get it done through a hospital. That’s a piece of the puzzle Amazon didn’t have. So diagnostics felt like a natural extension. And when you zoom out, the diagnostics space in India does look like a ripe opportunity. For context, right now, hospital labs control about 38% of the market. Standalone diagnostic centres take 37% and the big branded chains — the likes of Dr. Lal PathLabs and Thyrocare, hold the remaining 22%. But rewind to five years ago, and the picture looked different. Back then, standalone labs dominated nearly half the market, while big chains held just a measly 15%. Clearly, the winds have shifted. Source: finshots.in #healthcarestartup #dseidehealthcarenetwork

In his 123rd episode of “Mann Ki Baat” on June 29, 2025, Prime Minister Narendra Modi underscored the profound link between India’s heritage and public health. He emphasized the value of yoga for both physical and mental wellness, encouraging daily practice as a vital habit. He also noted that religious pilgrimages reinforce cultural well-being and foster social cohesion. A major announcement during the broadcast was that India has been declared Trachoma-free, marking a significant milestone in eradicating preventable diseases nationwide. Further, PM Modi reiterated that Ayurveda goes beyond treating illness—it promotes a holistic way of life, rooted in the ancient Indian philosophy of Vasudhaiva Kutumbakam (“the world is one family”). He highlighted India’s leading role in traditional medicine through initiatives like the WHO Global Centre for Traditional Medicine and India’s global promotion of wellness systems. He also emphasized the importance of technology in healthcare, noting the adoption of digital health IDs, telemedicine, and AI-driven monitoring of maternal and child health—citing over 340 million tele-consultations via India’s free telehealth services. timesofindia.indiatimes.com ✅ Key Takeaways: Yoga & Ayurveda: Central tools in promoting physical, mental, and societal well-being, with global acceptance through International Yoga Day and traditional medicine summits. Public Health Milestone: Declaration of India as Trachoma-free reflects national success in disease prevention. Digital Healthcare Integration: Use of advanced technologies and telemedicine to improve healthcare access across India. Source: ddnews.gov.in #healthcarestartupnews #dseidehealthcarenetwork

Star Health and Allied Insurance Company Ltd. (Star Health) India's largest retail health insurer, has entered into a strategic partnership with Medi Assist Healthcare Services Limited (Medi Assist), to adopt MAtrix platform, an advanced AI-powered claims platform. This collaboration is a significant step in Star Health's ongoing claims transformation journey, focused on delivering faster settlements, better customer engagement, and technology-led service excellence. The partnership will help in identification and elimination of fraud and reduction in waste and abuse through AI tools. Through the partnership Star Health Insurance is modernising its claims ecosystem to be future-ready. The platform will help the Company strengthen its ability to manage rising claim volumes while maintaining speed, consistency, and transparency in its operations. As part of this transformation, Star Health Insurance is scaling up its digital capabilities to meet growing service expectations from hospitals, policyholders and regulators. The use of the platform introduces intelligent automation, reduces manual steps, and streamlines workflows, enabling stronger turnaround performance across the network. Anand Roy, MD & CEO, Star Health and Allied Insurance said, "This marks a major step forward in strengthening our in-house claim management capabilities. This partnership is a key milestone in our journey to build a more agile and technology-driven claims ecosystem. Claims are at the heart of the insurance experience, and with Medi Assist's platform, we are enhancing speed, accuracy, and consistency, while keeping a keen eye on fraud, waste and abuse. By reducing manual interventions and standardising processes, we aim to strengthen efficiency and reinforce trust with our policyholders. This along with other initiatives being undertaken at Star Health Insurance will ensure our focus remains on delivering transparent, reliable, and customer-first claims service that meets the evolving needs of the health insurance and healthcare landscape." Echoing this sentiment, Satish Gidugu, CEO, Medi Assist said, "We are excited to collaborate on this transformative journey. This partnership is set to redefine industry standards in technology-driven insurance operations, ensuring an exceptional Policyholder experience." This integration represents a critical advancement in India's digital health insurance landscape combining innovation, operational readiness, and a sharper focus on policyholder outcomes. Source: indianpharmapost #healthcarestartup #starthealthinsurance #dseidehealthcarenetwork

Healthtech HR platform Jobizo has raised Rs 12 crore in a pre-Series A funding round led by Inflection Point Ventures, a Gurugram-based angel investment firm, along with Alkemi Ventures. The startup will use the raised funds to accelerate product innovation, scale marketing efforts, bolster team strength, and support working capital needs. Founded in December 2021 by Naveen Trehan and Avishek Agarwal, Jobizo said it is focused on addressing critical gaps in healthcare staffing from urgent short-term hiring and undertrained professionals to system-wide inefficiencies. Its online platform leverages smart technology to connect healthcare institutions with pre-verified professionals for both temporary and permanent roles. According to the startup, Jobizo has facilitated more than 18,500 temporary job placements and over 875 permanent hires across India. It has also supported over 1,000 international placements and maintains a verified pool of more than 60,000 healthcare professionals. "This round gives us the fuel to deepen our technology stack and expand across both domestic and international markets," says Avishek Agarwal, who is also the CEO of the company. "We are laser-focused on bridging the global healthcare skills gap while offering flexible, meaningful job opportunities. Strengthening our core team and launching in more cities will be a key part of our growth roadmap." Jobizo differentiates itself through its AI-enabled, real-time job-matching technology, which it claims enables faster and more precise placement of healthcare professionals. The platform currently offers coverage across India, including locum roles in Delhi NCR and Bengaluru, as well as permanent positions in multiple cities. Internationally, Jobizo operates a recruitment network spanning more than 41 countries, including the United Arab Emirates, South Africa, Kenya, and Nepal. The Indian healthcare hiring market is projected to reach $6.38–$12.76 billion by 2030, driven by rising demand, government reforms, and private investments. Globally, the market is poised to hit $62–$65 billion, fueled by aging populations, chronic disease burdens, and structural healthcare reforms. Vinay Bansal, Founder, Inflection Point Ventures, said, “Healthcare is an extremely important segment, and at the heart of it are people. Hence, it goes without saying, how crucial it is that the right people are hired for the job. However, the hiring process tends to be long, arduous and unreliable. Currently, healthcare is facing a major manpower crunch. It is reflected in the shortage and mismatch of healthcare talent. Jobizo is bridging the gap between healthcare and qualified professionals by making hiring faster, more flexible and digital thus solving multiple pain points across the healthcare employment ecosystem.” Source: indian startup news #healthcarestartupinindia #dseidehealthcarenetwork

Harpreet Singh Rai, who led Oura Ring from under $1 million to a $200 million revenue run‑rate, has been appointed President of Healthcare at Y Combinator‑backed Loop Health . This move marks Rai's return to full‑time startup leadership after leaving Oura in late 2021. Based between the US and India, he will oversee Loop's entire healthcare stack—including product, telehealth, diagnostics, and clinical services—and spend about half his time in India . Rai described India’s healthcare sector as undergoing a “UPI moment,” indicating a pivotal point in scaling digital-first, employer-led care innovations . His appointment aligns with Loop Health’s ambition to evolve from a B2B insurance provider into a comprehensive preventive healthcare platform. The startup, founded in 2018 and backed by investors like Elevation Capital and General Catalyst, has raised approximately $41 million to date . Source: moneycontrol.com #healthtechstartupindia #dseidehealthcarenetwork

Indian medical tourism platform Vaidam Health has acquired MediJourney, a digital-first international patient facilitation startup incubated by Ferns N Petals (FNP) in 2024. The deal, an all-cash transaction, marks a significant consolidation in India’s burgeoning cross-border healthcare ecosystem. MediJourney, launched last year, enables international patients to connect with verified hospitals and treatment providers using a tech-enabled matchmaking interface. The acquisition will allow Vaidam Health to integrate MediJourney’s proprietary digital infrastructure into its platform, advancing its capabilities in patient onboarding, AI-assisted navigation, and multilingual case coordination. “We welcome MediJourney to Vaidam Health,” said Pankaj Chandna, Co-Founder of Vaidam Health. “MediJourney’s platform complements our infrastructure and broadens our ability to connect international patients with trusted healthcare options in India. This acquisition reflects our commitment to simplifying access to quality treatment for patients worldwide.” Founded in 2016 by Chandna and Manish Chandra, Vaidam Health facilitates over 25,000 monthly patient interactions and has an operational footprint spanning seven countries. The company provides a suite of services for medical travelers—including treatment discovery, visa facilitation, interpreter support, and post-care engagement—with a strong network of partner hospitals across India. MediJourney will continue to operate independently under Vaidam’s ownership, with its core team focusing on new strategic opportunities. Rishabh Jalan, Co-Founder of MediJourney, said, “This acquisition represents a powerful synergy between two companies that share a common vision for innovation and customer-centric solutions. By joining forces with Vaidam Health, we are ensuring that our technology and expertise reach new heights, benefiting a wider audience while allowing us to focus on new strategic opportunities.” The acquisition is projected to result in a 40 to 50% increase in active patient engagements over the next year, supported by Vaidam’s existing presence in international markets. The company plans to double down on its in-country teams and information centers in Africa and Southeast Asia to meet rising demand. Source : indian startup news #healthcarestartupindia #dseidehealthcarenetwork

Pristyn Care has ramped up its hospital expansion strategy with the launch of three new digitally integrated hospitals in Gurgaon, Hyderabad, and Kochi, bringing its total number of owned facilities to eight, just four months after opening its first. This move also marks the startup’s entry into South India. Pristyn Care now operates a clinical footprint of 200,000 sq ft, comprising 400 beds, more than 20 modular operating theatres, over 50 ICU beds, and a team of over 550 medical professionals. The latest launch follows the company’s earlier announcement in February 2025, when it unveiled its first five hospitals within a span of just 75 days. That rapid rollout, focused around Delhi-NCR, was a significant pivot from Pristyn’s earlier asset-light model of partnering with hospitals to offering in-house surgical care. Now, with the addition of 90,000 sq ft across three cities, Pristyn is doubling down on its promise of accessible, seamless healthcare. Each new facility is being integrated with the company’s proprietary digital platform, which includes real-time clinical alerts, EMRs, express discharge tooling, and one-tap insurance approvals. “We are not starting from scratch; the technology is built and live. Our next task is to stitch it into each new hospital so patients experience shorter waits, clearer communication, and truly joined-up care, said Dr Vaibhav Kapoor, Co-founder of Pristyn Care. Pristyn Care’s new hospitals bring tailored services to each city, Gurgaon boosts neonatal and women’s health, marking its sixth facility in NCR; Hyderabad offers 24×7 trauma care and tech-led joint replacements; and Kochi adds emergency care with a riverside rehab wing for Kerala patients. Notably, Pristyn Care’s first hospital in Delhi hit double-digit profitability within eight weeks. With the strong performance metrics, the company is now targeting 50 hospitals by FY28, with upcoming launches in Mumbai, Bengaluru, and Pune. Source: Medical Buyer #healthcarestartupindia #dseidehealthcarenetwork

Often, many of us don’t get a doctor consultation for minor medical issues as doctors often don’t do home visits. Gurugram-based Kyno Health is solving for that. Founded in 2023 by Aditya Gupta, who previously worked at Pristyn Care, Kyno Health is a hyperlocal healthtech startup that offers quick general physician home visits for acute, non-emergency cases. The startup enables patients to book a home visit from a certified physician who can arrive in around 20 minutes. Over the past two years, the company says it has completed over 23,000 consultations, maintained an average travel time of 25 minutes, and achieved a 91% patient satisfaction rate. “We’re focused on creating a new category in primary care. While others serve chronic care or post-hospitalisation needs, we’re targeting real-time acute use cases—things like high-grade fever, sudden BP fluctuations, or gastric issues—that need attention within the hour but don’t warrant an ER visit,” the founder tells YourStory. How does it work? Kyno Health’s doctors—all with MBBS degrees and at least five years of experience—arrive at the patient’s home with a nurse, diagnostic support (if needed), and basic medicines in hand. Each consultation lasts 25-30 minutes, notably higher than India’s average of 4-5 minutes per consultation. “We’re trying to fix the foundation. The quality of diagnosis and medical outcomes improves when time is invested in the consultation. A rushed diagnosis often leads to overprescription or misuse of antibiotics,” he adds. Currently accessible via a web app, the startup has kept its service flow simple: users enter three basic details (name/age, symptoms, location), get an estimated time of arrival, make the payment, and are then assigned a doctor whom they can track live via the platform. Doctors, meanwhile, get alerts on their app and have cabs that are ready for dispatch. The startup partners with multiple vendors, including ZiT, Carzonrent, and WTI, for hiring cabs. Post-consultation, for medicines or nursing procedures, Kyno Health has an in-house nursing team of 38 doctors and 20 nursing staff who provide essential services. Medicines and diagnostics are offered through third-party vendors, including Portea and Health Care at Home. It also has a dedicated corporate team of 7-8 members who ensure seamless coordination for the patient. While the startup doesn’t yet provide medicine-only delivery, doctors carry all basic and emergency medicines during home visits. The system also maintains patient records securely on the backend. Doctors can view past prescriptions and visit notes through the internal app. Patients receive their handwritten prescriptions for now. A digital Electronic Medical Record (EMR) feature is in development, with the goal of building a voice-led EMR too. Source: Your story #healthcarestartupstory #dseidehealthcarenetwork

Miltenyi Biotec India Pvt. Ltd. and the Biotechnology Industry Research Assistance Council (BIRAC) have entered into a strategic Letter of Intent (LoI). The collaboration, formalised during the ongoing BIO International Convention 2025 in Boston, reflects a shared vision to enhance indigenous capabilities in next-generation therapeutics. The agreement outlines a multifaceted roadmap to advance India’s CGT capabilities, ranging from workforce training and translational research to point-of-care (PoC) CAR-T manufacturing and startup mentorship. This partnership is expected to play a pivotal role in transforming India into a global centre of excellence in advanced therapies. As part of the ceremonial occasion, Miltenyi Biotec India had the distinction of inaugurating the India Pavilion alongside senior dignitaries from BIRAC and the Department of Biotechnology (DBT). The ribbon-cutting ceremony symbolised India’s growing influence in the global biotech innovation space. The core pillars of the collaboration include: Capacity Building: Launching comprehensive training programs to upskill clinicians, scientists, and technicians in CGT manufacturing, analytics, and quality control. Research Collaboration: Driving academic and multi-centre clinical studies that address pressing medical needs, especially in the fields of oncology, autoimmune disorders, and rare diseases. Localised Manufacturing: Establishing PoC CAR-T centres across the country using Miltenyi’s CliniMACS Prodigy system, a move aimed at making cell therapies more accessible and cost-effective. Startup Ecosystem Support: Encouraging innovation by identifying and nurturing Indian biotech startups, aligned with the ‘Make in India’ initiative, and enabling local production of critical components. Commenting on the development, Priya Kapoor-Hingorani, Managing Director of Miltenyi Biotec India, said, “The potential of India draws us. Our partnership with BIRAC focuses on updating and upskilling scientists to strengthen the country’s scientific capabilities and infrastructure. Together, we’re exploring how to address current unmet needs in medical science, particularly in areas like autoimmune and rare diseases by enhancing access through innovative mechanisms such as point-of-care CAR-T and graft engineering.” Dr. Jitendra Kumar, Managing Director, BIRAC, also emphasised the strategic significance of the collaboration, stating, “The government is signing this Letter of Intent with a multinational company renowned for its expertise in cell and gene therapy. India aspires to become a global leader in this space, and achieving that goal requires a strong foundation of skilled manpower. Miltenyi has committed to supporting this vision by contributing to training and capacity building.” Source: eHealth #healthcarestartupindia #dseidehealthcarenetwork

Quadria Group, one of Asia’s most prominent healthcare-focused private equity firms, has unveiled the third edition of its HealthQuad fund, targeting a raise of up to $300 million, comprising a $200 million target corpus and a $100 million greenshoe option. HealthQuad Fund III builds upon the success of its predecessors, Funds I and II, which backed more than 18 tech-enabled healthcare ventures across diagnostics, mental health, e-pharmacy, and data analytics. Qure.ai, Medikabazaar, Ekincare, Wysa, and Redcliffe Labs are some of its portfolio companies. Launched in 2016 as a specialized vehicle distinct from Quadria’s flagship fund, HealthQuad has focused on identifying early-growth opportunities that improve access, affordability, and outcomes in India’s fragmented healthcare landscape. The new fund, according to the firm, will continue to back ventures across South Asia, Southeast Asia, and the GCC, with a focus on scaling impact across the primary, diagnostic, and chronic care spectrum. In a significant structural move, Quadria’s co-founders Dr. Amit Varma, Abrar Mir, and Sunil Thakur will now assume full ownership and operational control of HealthQuad following its separation from KOIS. A major portion of the existing investment and committee members will remain involved in managing current portfolio investments. The team is also set to expand, with additional hires expected across investing, operations, and clinical domains. "India presents one of the world's most compelling healthcare investment opportunities—driven by growing demand, digital acceleration, and underserved segments across primary, diagnostic, and chronic care," said Dr Amit Varma, Co-founder and Investment Committee Member, HealthQuad. "With expanded leadership, we are better positioned than ever to deliver cross-regional value across South Asia, Southeast Asia, and the GCC." HealthQuad’s next phase comes on the heels of Quadria’s recent closure of its flagship Quadria Capital Fund III at $1.07 billion. The firm currently manages more than $4 billion in assets across 27 portfolio companies, with exposure in India, Vietnam, Indonesia, Malaysia, and Singapore. "HealthQuad is not just a fund—it's Quadria's conviction in motion," said Abrar Mir, Co-founder and Investment Committee Member. "We've built a unique platform supporting diverse healthcare models, accelerating their growth with our powerful ecosystem." Source: Indian Startup News #healthcarestartupindia #dseidehealthcarenetwork

New Delhi, 17th June 2025: Online Chikitsa Mitra (OCM), India’s leading health-tech start-up, is proud to announce the launch of its mobile app, a groundbreaking step toward expanding healthcare access across India by enabling direct, in-home consultations. This first-of-its-kind app offers consultations with specialized doctors in both Hindi & English. Founded in 2016, OCM started off in rural India by setting up e-clinics through local medical stores. Having connected thousands of rural residents to quality healthcare, facilitating over 120,000 consultations across 15+ states through its 550+ e-clinic network, OCM will now offer digital consultation pan-India through its newly launched app. This will give direct accessibility to the end users, thereby removing geographical barriers and enabling timely consultations with qualified specialists, general practitioners and wellness advisors, from anywhere in the country. In a nation of 1.44 billion people, only 12% regularly speak English. However, it has the world’s second-largest internet population at over 1.2 billion mobile users. Recognizing this disparity, the OCM app provides an intuitive, bilingual interface that bridges the gap, empowering patients to engage with healthcare professionals more readily than ever before. According to the Health Dynamics of India 2022-23 report from the Union Health Ministry, nearly 80% of rural community health centers (CHCs) face a shortage of specialized doctors. OCM’s app addresses this critical gap by providing an array of specialists in fields like cardiology, orthopedics, gynecology, pediatrics, and more, expanding healthcare options for underserved regions. “Our ultimate goal is to make healthcare a right, not a privilege, for all by scaling technology-driven solutions that meet evolving healthcare needs. With our mobile app, we are embracing the digital transformation sweeping across India to bring healthcare to the fingertips of people in even the remotest of locations,” said Smriti Tandon, Co-founder of OCM. Adding to this, Shubhang Tandon, Co-founder of OCM shared, “The shortage of specialists in semi-urban and rural healthcare facilities is a reality that affects millions. Through our app, we’re utilizing technology to connect these patients with top-tier specialists, empowering communities with a lifeline that’s convenient, effective, and life-changing.” Patients can easily schedule appointments, engage in secure video consultations, and receive digital prescriptions through the app. It is available for download on both Android and iOS platforms. Looking ahead, OCM aims to onboard more doctors across various specialties and achieve 1,000 consultations per day by the end of 2025-26. Source: passionate in marketing #healthtechstartup #dseidehealthcarenetwork

The Chief Minister emphasized that improving healthcare and medical education is a top priority for his government, not only to ensure better patient care but also to raise Telangana’s reputation in the national medical education landscape. He instructed health officials to coordinate closely with the Union Health Ministry to expedite pending approvals for new colleges and secure additional central funding where needed. The reforms will also include upgrading hospital infrastructure, streamlining administrative systems, and implementing real-time digital dashboards to monitor performance indicators across all government medical colleges and hospitals. Revanth Reddy also underscored the importance of timely execution, directing that funds be released without delay and responsibilities clearly assigned to senior officers. Additionally, the government aims to make Telangana a hub for skilled nursing professionals by integrating language training—starting with Japanese—into nursing curricula, in collaboration with the Japanese government. This move is intended to increase overseas employment opportunities for nursing graduates. The Chief Minister’s overhaul plan is being viewed as a proactive response to institutional challenges that have persisted for years, and as a foundational step toward building a more accountable, efficient, and globally relevant public healthcare system in Telangana. Source: The economic times #healthcarefunding #dseidehealthcarenetwork

India has been one of the top recipients of remittances in the world for more than a decade. Inward remittances jumped from $55.6 billion in 2010-11 to $118.7 billion in 2023-24, according to data from the country’s central bank. The bank projects that figure will reach $160 billion in 2029. This means there is an increasing market for digitalized banking experiences for non-resident Indians(NRIs), ranging from remittances to investing in different assets back home. Aspora (formerly Vance) is trying to build a verticalized financial experience for the Indian diaspora by keeping convenience at the center. While a lot of financial products are in its future roadmap, the company currently focuses largely on remittances. “While multiple financial products for non-resident Indians exist, they don’t know about them because there is no digital journey for them. They possibly use the same banking app as residents, which makes it harder for them to discover products catered towards them,” Garg said. In the last year, the company has grown the volume of remittances by 6x — from $400 million to $2 billion in yearly volume processed. With this growth, the company has attracted a lot of investor interest. It raised $35 million in Series A funding last December — which was previously unreported — led by Sequoia with participation from Greylock, Y Combinator, Hummingbird Ventures, and Global Founders Capital. The round pegged the company’s valuation at $150 million. In the four months following, the company tripled its transaction volume, prompting investors to put in more money. The company announced today it has raised $50 million in Series B funding, co-led by Sequoia and Greylock, with Hummingbird, Quantum Light Ventures, and Y Combinator also contributing to the round. The startup said this round values the company at $500 million. The startup has raised over $99 million in funding to date. After pivoting from being Pipe.com for India, the company started by offering remittance for NRIs in the U.K. in 2023 and has expanded its presence in other markets, including Europe and the United Arab Emirates. It charges a flat fee for money transfer and offers a competitive rate. Now it also allows customers to invest in mutual funds in India. The startup markets its exchange rates as “Google rate” as customers often search for currency conversion rates, even though they may not reflect live rates. The startup is also set to launch in the U.S., one of the biggest remittance corridors to India, next month. Plus, it plans to open up shop in Canada, Singapore, and Australia by the fourth quarter of this year. Source: yahoo finance #healthcarestartupindia #dseidehealthcarenetwork

Here are the latest reports on this tragic incident: A Boeing 787‑8 Dreamliner, Air India Flight AI 171, bound from Ahmedabad to London, crashed just 30 seconds after takeoff on June 12, 2025. The aircraft struck the dining hall of the doctors’ hostel at B.J. Medical College around lunchtime, causing a devastating fireball  Tragically, 241 of 242 people on board were killed, with only one survivor  On the ground, initial reports confirm 24 fatalities, including four MBBS students, a doctor’s wife, and other residents; two more students are still missing  Key victim data: The four MBBS students were from B.J. Medical College—two first-year and two second-year undergraduates  Two students remain unaccounted for . The flight data recorder (black box) has been recovered from the debris atop the hostel mess building and is being analyzed for clues on factors like engine thrust, flap settings, and landing gear  Preliminary investigations focus on possible mechanical or procedural issues during takeoff  In response, India’s aviation regulator has ordered additional safety inspections on all Boeing 787‑8/9 aircraft in Air India’s fleet  International agencies, along with Boeing and GE Aerospace, are collaborating in the investigation  ⚠️ This remains India’s deadliest aviation tragedy in over 30 years, and families of the victims—including medical students—are receiving support. DNA testing is underway to confirm identities Source: onmanorama #AirIndiaCrash #BJMedicalCollege #MedicalStudents #AhmedabadCrash #dseidehealthcarenetwork

In India, the first 1,000 days of a child’s life are rightly viewed as critical to nutrition, brain development, and immunity. But one equally essential area often goes overlooked: skin health. For millions of Indian parents, the daily routine of massaging, bathing, and moisturising newborns has remained unchanged for generations. Yet, the products they use are often poorly suited for Indian skin, water, and climate. Dr. Sonali Kohli, ( a board-certified dermatologist with over a decade of experience with handling skin ), first encountered this gap not just in her clinic, but in her own home. This frustration became the founding insight behind EDA Baby & Child, a dermatology-led skincare startup that wants to revolutionise how Indian parents think about baby skincare. What began as a personal need has now grown into a science-first consumer brand with a clear mission: to build India’s first clinically validated, complete child wellness ecosystem. Solving the cracks in the international formula There’s no doubt the global baby skincare market is booming—expected to reach $20.3 billion by 2031, according to Transparency Market Research—but Indian parents are beginning to question the dominance of international brands. The underlying issue? Indian babies are fundamentally different ( in their genetics and environmental exposure). Baby skin barrier is 40% thinner than adults and far more permeable to pollutants, allergens, and pH imbalance from hard water or harsh soaps. And beyond biology, the everyday environmental stressors in Indian cities—dust, heat, varying humidity—require tailored skincare solutions. Through her clinical practice, Dr. Kohli observed that global formulations, though well-researched for Western environments, were inadequate in India. “International brands can many a times overlook the differences in Indian skin genetic predisposition, melanin levels, and our water’s mineral composition,” she explains. To build EDA, she spent two years studying baby skin reactions and rashes across India’s micro-climates—from the humid coastlines of Kerala to the dry winters of North India. The result is a line of ceramide-rich, barrier enhancing, pH-balanced formulations engineered for Indian skin. Source: Indian startup news #healthcarestartup #dseidehealthcarenetwork

Deep‑Tech Revolution in India 1. Government-Fueled Momentum Major funding boosts: Initiatives like the India AI Mission (₹10,372 crore over five years) and proposed deep-tech fund (₹20,000 crore) are propelling innovation Policy frameworks taking shape: Policies such as the National Deep Tech Startup Policy aim to streamline ecosystem growth from R&D to scaling 2. Startup Ecosystem Gains Ground Robust startup numbers: Over 3,600 deep‑tech startups exist in India today, including nearly 500 launched in 2023 alone Global competitiveness: Ranked 6th globally for deep-tech startups—AI dominates, showing 74% of new ventures and 86% of funded ones tied to AI 3. Sector Focus & R&D Intensity Core verticals targeted: AI, ML, robotics, quantum, biotech, advanced materials, drones, and blockchain are at the forefront drishtiias.com Long R&D cycles, far-reaching impact: Deep-tech requires intensive investment and patience but holds the promise of disruptive breakthroughs 4. Funding & Investment Trends Rising capital inflows: Globally, deep-tech is garnering 20% of annual VC funds (~$40 billion in 2023)—mirrored by India’s. India-specific investments: Deep‑tech startups like Observe.AI have logged major funding (e.g. $214 M), while national policy funds are being calibrated to match demand drishtiias.com . 5. Opportunities & Challenges 👉 Strengths: Deep talent pool—~1.5 million engineering grads annually—fuels innovation DPI backbone (UPI, Aadhaar, ONDC) supports scalable digital solutions . ⚠️ Challenges: Regulatory hurdles, commercialization lag, talent shortages, and infrastructure limitations persist Execution gaps are noted—policy intent doesn't always translate into action without public-private collaboration . 6. The Role of Thought Leaders Influencers like Jeenendra Bhandari (often leading deep-tech councils and VC platforms) typically emphasize: Aligning policy with operational execution. Encouraging patient, long‑term capital for high‑risk deep-tech ventures. Strengthening academia-industry synergies for commercializing R&D. Building market access pathways through anchor customers and public procurement. Source: Economic times #healthcarestartupindia #dseidehealthcarenetwork

Apollo Hospitals Enterprise Ltd. has shown significant market activity, maintaining its opening price throughout the trading session. The company has outperformed the Sensex over the past year, with a market capitalization of Rs 98,775.75 crore and a P/E ratio above the industry average, reflecting strong earnings potential. Apollo Hospitals Enterprise Ltd., a prominent player in the hospital and healthcare services sector, has shown notable activity today, reflecting a complex market environment. The stock opened at Rs 6,842.45 and has maintained this price throughout the trading session. Despite a slight decline of 0.07% today, Apollo Hospitals has outperformed the Sensex over the past year, achieving a return of 15.34% compared to the Sensex's 8.29%. The company's market capitalization stands at Rs 98,775.75 crore, categorizing it as a large-cap entity. With a price-to-earnings (P/E) ratio of 68.36, Apollo Hospitals is positioned above the industry average P/E of 54.05, indicating strong earnings potential relative to its peers. In terms of moving averages, the stock is currently higher than its 100-day moving average but lower than its 5-day, 20-day, 50-day, and 200-day averages, suggesting a mixed short-term performance. The broader hospital and healthcare services sector has seen 41 stocks declare results, with 13 reporting positive outcomes, indicating a competitive landscape. Overall, Apollo Hospitals continues to demonstrate resilience in a fluctuating market. Source: marketsmojo #healthcarenews #dseidehealthcarenetwork

Tracxn’s India Pharma and Healthcare Funding Tracker for May 2025 reveals a major recovery in funding activity. Total funding reached $254.7 million across 10 rounds, representing a 462.36 per cent increase from April 2025 and a 44.20 per cent rise from the same month last year. Seed-stage funding dominated with 61.9 per cent of total funding. Early-stage funding contributed 18.0 per cent, while late-stage funding comprised 20.1 per cent of the total. PB Healthcare secured funding of $156 million followed by Vetic ($26.2 million), Pharmazz: ($25.0 million), CureBay ($21.0 million), The Good Bug ($11.9 million), and DentCare ($10.6 million). In May 2025, several prominent venture capital firms made notable investments in the startup ecosystem. Bessemer Venture Partners participated in a funding round for Vetic, while Bertelsmann India Investments backed CureBay, and SIG Venture Capital invested in The Good Bug. Each of these firms was involved in one funding round, highlighting selective but strategic investment activity during the month. Key Takeaways: 1. Massive recovery in funding: Funding surged more than 5 times compared to April 2025. 2. Seed-stage rounds lead: Seed investments made up the largest share at over 60 per cent. 3. The top deal alone ($156 million) drove the majority of funding. This surge suggests renewed investor confidence and growing momentum in India’s pharma and healthcare startup ecosystem. Source: Express Healthcare #healthcarestartupfunding #dseidehealthcarenetwork

At the CII Annual General Meeting, startup founders and investors called for the need for policy stability, more patient capital, and global competitiveness, even as India emerges as a hub for innovation and entrepreneurship. Rajat Verma, founder and CEO of battery recycling startup Lohum, pointed out the mismatch between India’s global ambitions and the depth of its private capital markets. “There’s no dearth of engineering talent or market opportunity,” he said, “but a lot of promising deep-tech entrepreneurs are unable to scale simply because long-gestation sectors lack the capital support they need.” Drawing on InMobi’s journey from a scrappy startup in 2007 to one of the world’s largest independent ad tech firms, Dr Subi Chaturvedi, global senior VP at InMobi emphasised that the current startup generation doesn’t seek subsidies or hand-holding—just clarity. “Policy cannot be an afterthought,” she said. “What we need is consistency, not volatility. Without that, global investors will hesitate to back Indian innovation.” On the other hand, Paavan Nanda, CEO and co-founder of WinZo Games thinks that what every entrepreneur in India needs is “exposure”. “Exposure is the single most important unlock that any entrepreneur can get, especially if they're looking to expand globally. We're talking about Indian games to hold top 3 ranking across all countries.” The discussion also turned to the broader issue of narrative—how Indian startups are viewed, both at home and abroad. Suhel Seth, who joined the panel to provide an outside-in view, didn’t hold back. “Today, the startup ecosystem is largely measured by valuations and unicorn status,” he said, “but that’s not the right yardstick. The real question is—are we solving unique, replicable problems that change how people live, behave, and consume?” He added that Indian startups must lead not just with scale, but with pride and values. “Why haven’t we built a Google or Facebook? It's because we often celebrate exits more than endurance,” Seth said, urging founders to spotlight impact over investor returns. Healthcare, gaming, deep tech and financial inclusion were all cited as sectors where Indian companies could lead globally—but only if backed by the right ecosystem. Siddhartha Nihalani, CEO and co-founder of Practo, noted that India is well-placed to become a hub for medical tourism, but needs to resolve challenges around global credentialing and remote care. “We’ve got the doctors, the hospitals and the tech. But there are regulatory challenges around education, around privileging these doctors in their respective countries, which is something that governments of countries can work together and figure out – and which country recognises which medical degree across countries.” Throughout the discussion, the emphasis remained on thinking big—but thinking Indian. 60% of the cost of any military equipment today is made up of electronics – 35% of that is semiconductors. China's penetration of that market has increased 600%, including U.S. defence supply chains in the last couple of years from 2004 to 2022. And what’s more, by 2030, China will have 65% of global capacity on semiconductors and electronics for defence. “That's the piece that we're up against. Now, why India? India is the only country with enough skilled manpower to be able to compete with China. Why? Because since the 70s, American companies have come to India, European companies have come to India and set up huge tech centres over here. So, our GCCs are finally paying off,” explains Vrinda Kapoor of 3rdiTech. 20% of the world's entire semiconductor design talent sits out of three Indian cities – Bangalore, Hyderabad and Mumbai. Qualcomm's 5G chip was 100% designed in India. Source: fortuneindia #healthcarestartup #dseidehealthcarenetwork

Qure.ai, the fast growing Indian health-tech startup that offers artificial intelligence (AI) solutions for medical diagnostics, is planning to go public in next two years, says its co-founder and CEO Prashant Warier. Founded in 2016 and headquartered in Mumbai, Qure.ai has developed advanced AI algorithms that help healthcare providers detect critical conditions like tuberculosis, lung cancer and stroke risks. These tools that analyse medical images to give fast and accurate diagnosis are being increasingly used in regions with shortage of trained radiologists. Warier stated in media, “We look to break even and be profitable next financial year. As we sort of get to that break-even, we can start planning. And maybe in two-and-a-half years or two years is the earliest we can do an IPO.” The company has already got significant backing from global investors. Qure.ai has raised USD 125 million (~INR 1,063 crore) so far with Fractal Analytics, Peak XV Partners and Novo Holdings—the investment arm of Danish pharma giant Novo Nordisk—as its top backers. Global Expansion with US as Key Market Qure.ai’s solutions have got traction with major global healthcare players. Its client list includes AstraZeneca, Medtronic and Johnson & Johnson MedTech with whom it is partnering in India to detect early lung cancer. Currently, US accounts for around 25% of the company’s revenue, making it Qure.ai’s largest market. The company is now looking to go deeper in US through new partnerships. At the same time, it is also focusing on expansion in low and middle income regions in Latin America and Africa to bridge diagnostic gaps in underserved healthcare systems. Interestingly, India is a minor market contributing less than 5% of overall revenue. Growth Trajectory in a Booming Industry Qure.ai has seen 60–70% annual revenue growth and Warier expects this to continue for next five years. The company currently sees around 15 million patients globally each year and this number will go up as AI driven diagnostic tools become more mainstream. The optimism around Qure.ai is in line with industry trends. The global AI in healthcare market which is estimated to be USD 14.92 billion (~INR 1.26 lakh crore) in 2024 is expected to reach USD 110 billion (~INR 9.36 lakh crore) by 2030 as AI tools for early disease detection, workflow automation and reducing the burden on overworked healthcare professionals gain traction. Strategic Outlook While profitability is the goal for next financial year, an IPO is clearly on the cards. Warier said achieving financial sustainability will be a key milestone before public listing. With its pioneering AI technologies, international clientele, and expanding footprint across developed and emerging markets, Qure.ai is positioning itself as a formidable player in the global health-tech landscape. If current growth trends continue, the company could well be one of India’s most prominent AI-based healthcare success stories to enter the public markets in the near future. For more details related to IPO GMP, SEBI IPO Approval, and Live Subscription stay tuned to IPO Central. Source: ipocentral.in #healthcarestartup #dseidehealthcarenetwork

Fintech dominated the sector-wise distribution with three deals, followed by strong performances from e-commerce and media and entertainment. This week’s funding activity featured five growth-stage and 13 early-stage deals, with three startups choosing to keep their funding amounts private. Mumbai: Indian startups raised $139.5 million this week across 21 deals -- reflecting continued investor confidence despite broader market uncertainties. This week’s funding activity featured five growth-stage and 13 early-stage deals, with three startups choosing to keep their funding amounts private. Delhi-NCR emerged as the leading region with eight deals, followed by Bengaluru with four. Startups from Mumbai, Chennai, Bhubaneswar, and Ahmedabad also featured in this week’s funding round-up. Source: freepressjournal #healthtechstartup #dseidehealthcarenetwork

E-clinic startup CureBay in India has bagged $21 million in a Series B funding round led by Bertelsmann India Investment. Elevar Equity and British International Investment also joined the fundraising event. Since launching in 2021, the company now has a chain of over 150 rural e-clinics across the states of Odisha and Chhattisgarh, employing over 1,000 community health workers, or Swasthya Mitras, who are trained to facilitate teleconsultations, diagnostic tests, medicine order and delivery, and hospital admission and concierge services. CureBay offers a preventive health service package to which around 90,000 are actively subscribed. WHAT IT'S FOR With its fresh funds, CureBay plans to deploy proprietary AI-powered algorithms to enable workflow automation and enhance the predictive capabilities of its rural e-clinic network. The startup has already integrated machine learning, generative AI, and Internet of Things diagnostics into its technology platform. "The capital will help us scale technology, talent, and reach to bring dignified, affordable healthcare to the last mile," added founder and CEO Priyadarshi Mohapatra. CureBay raised more than $13 million in Series A funding in two rounds over the past three years to build its network. It targets to set up 200 e-clinics in rural India. MARKET SNAPSHOT Indian health tech startups developing or integrating AI into their technology stack have attracted the most investments in recent years. For example, medical imaging startup Qure.ai raised $65 million in Series D funding in September, while dermatology startup Cureskin raked in $20 million in Series B funding in March last year. Dozee, which offers an AI-powered contactless vital signs monitoring and alert system, seeks to enter more international markets with its latest $8 million investment. Kauvery Hospital, through its investing arm, Healthcare Capital, provided undisclosed funding to remote patient monitoring system developer Lifesigns to help augment its AI and predictive algorithm capabilities. Early this year, BrainSight AI, which develops an AI-powered brain mapping platform, scored $5 million in pre-Series A funding, while Consint.AI, which offers generative AI-driven insurance technology solutions, raised $500,000 in seed funding. Source: mobihealthnews #healthcarestartup #fundingindia #dseidehealthcarenetwork

Lightbox-backed Zeno Health (erstwhile Generico) has launched a platform to incubate and support early stage healthcare startups. The platform, Pay It Forward, aims at nurturing healthcare and wellness startups operating in medicines, diagnostics, insurance, hygiene and nutrition categories. “Early stage healthcare and wellness startups working in medicines, diagnostics, insurance, hygiene, nutrition, preventive care, derma, OTC, or any other product or service that makes healthcare better and more accessible are invited to apply…,” Zeno Health said in a statement. With the initiative, the company looks to help startups by providing them retail shelf space and visibility in nearly 180 pharmacies and stores across Mumbai and Pune. The Mumbai-based startup claims to offer access to its consumer base and mentorship from its founders and leadership team. As per its statement, the programme will help startups that are providing quality healthcare at affordable costs. Founded by IIT Bombay alumni Girish Agarwal and Siddharth Gadia in 2017, Zeno Health is an omnichannel pharmacy network which sells generic medicines. It claims to offer medicines at 60% lower cost by sourcing them directly from manufacturers. Besides retail pharmacy stores, it has 200 micro-franchises across Maharashtra and West Bengal. Zeno Health also has a private label brand GoodAid which sells generic medicines. “Through ‘Pay It Forward’, we want to create a founder-first platform that helps startups bring impactful solutions to the people who need them most. We’re not taking equity. We’re not doing this for credit. We’re doing it because India needs more healthcare disruptors…,” said Agarwal. The development comes nearly over two months after the healthcare startup launched a 50-minute medicine delivery service in Mumbai. Prior to that, Zeno Health raised $25 Mn in its Series C funding round led by South Korean private equity firm STIC Investments and existing investor Lightbox. Back then, it said that the capital would be used to expand footprint, spruce up tech infrastructure, branding and building innovative solutions for diverse markets. Source: inc42 #healthcarestartupindia #dseidehealthcarenetwork

Meghalaya Chief Minister Conrad K Sangma presented a Rs 1 crore check to Dr Norman Tunnel Hospital in Jowai today as part of the state's ongoing healthcare improvement efforts. The funding represents the first installment of a larger Rs 2 crore commitment to the hospital under the Meghalaya Health Advancement Policy, which aims to strengthen non-profit healthcare institutions throughout the state. "Dr Norman Tunnel Hospital is the fifth private hospital to benefit from this support, empowering it to continue its vital service to the community," Sangma noted in his social media announcement. This latest disbursement follows a similar Rs 1 crore allocation to Holy Cross Hospital in Tura earlier this month in May, highlighting the government's systematic approach to enhancing medical infrastructure across different regions of Meghalaya. The Chief Minister expressed gratitude to the KJP Assembly and acknowledged the dedication of healthcare professionals at Norman Tunnel Hospital, recognising their contributions to public health in the region. The Meghalaya Health Advancement Policy represents a targeted investment in the state's healthcare delivery system, with particular focus on supporting non-profit institutions that serve communities at the grassroots level. Source: India Today #healthcarestartupindia #dseidehealthcarenetwork

Rajasthan, May 20, 2025: In an inspiring achievement for India’s startup and healthcare landscape, Khet Singh Rajpurohit, co-founder of the fast-rising health-tech platform ClaimBuddy, has been named to the prestigious Forbes 30 Under 30 Asia 2025 list. Featured in the Health & Technology category, Khet is one of only four Indians to be recognized this year—making his inclusion not only a personal milestone, but a symbolic breakthrough for India’s underrepresented health-tech sector on the global stage. ClaimBuddy is transforming how patients and hospitals navigate health insurance, a space long plagued by complexity and delay. The platform leverages technology to streamline the claims process at the point of care—offering patients speed, clarity, and confidence during moments of medical stress. To date, the platform has facilitated over ₹500 crore in insurance claims across 250+ partner hospitals in more than 10 cities. It has also raised $8 million in venture capital funding, including a $5 million Series A round in April 2024 led by Bharat Innovation Fund, with participation from CAC Capital, Chiratae Ventures, and Rebright Partners. Khet’s story is one of perseverance and purpose. Born in the small village of Ghevra in Rajasthan and raised in Ludhiana, Punjab, he worked his way through academic excellence—scoring above 95% in Class 12—and went on to complete his MBA from the Indian Institute of Management (IIM) Bangalore. Forgoing campus placements, he chose the path of entrepreneurship and co-founded ClaimBuddy to tackle the chaos of India’s insurance system at a time when patients need support the most. “This recognition is not just personal—it belongs to every small-town dreamer, every underdog who chooses to solve a real problem with grit, empathy, and technology,” said Khet Singh Rajpurohit. His selection to the Forbes 30 Under 30 list shines a spotlight on the urgent need for innovation in healthcare infrastructure and reinforces the potential for Indian startups to lead globally in digital health transformation. About ClaimBuddy: ClaimBuddy acts as a one-stop solution for health insurance claim assistance for patients and hospitals. The company is building a robust ecosystem to ensure hassle-free insurance claims by leveraging technology and a set of simple yet powerful processes. Source: SugarMint #healthtechstartupindia #dseidehealthcarenetwork

CureBay, a health-tech startup focused on enhancing rural healthcare access in India, has secured $21 million in a funding round led by Bertelsmann India Investments. This investment underscores the growing interest in innovative health-tech solutions that bridge digital and physical healthcare services. Strategic Expansion and Impact Founded in 2021, CureBay operates a hybrid healthcare model combining technology with a network of eClinics and trained local health workers, known as Swasthya Mitras. This approach has enabled the company to serve approximately 55,000 patients each quarter and enroll 18,000 members in its subscription-based healthcare plans. Currently, CureBay reaches over 18 million people across Odisha and Chhattisgarh, with plans to expand its services to 100 million rural residents across 16 regions in six states, including Jharkhand, Bihar, Uttar Pradesh, and Madhya Pradesh. Technological Advancements The company is developing one of India's largest rural health databases, leveraging AI and data monetization strategies. Through its AI-powered healthcare ecosystem, CureBay Quantum, the platform analyzes rural health trends, enabling targeted outreach and personalized care. Financial Performance CureBay has recorded an eightfold increase in Gross Merchandise Value (GMV) during the first half of FY25 compared to the same period in FY24. The company has reached an Annual Recurring Revenue (ARR) of ₹1,284 million and aims to achieve ₹2,000 million by March 2025. This funding round follows a previous investment of ₹62 crore in January 2024, led by Elevar Equity, which supported CureBay's expansion and technological enhancements. With the new capital infusion, CureBay plans to further expand its network of eClinics, enhance its technological capabilities, and deepen its penetration into underserved markets, reinforcing its commitment to delivering affordable and high-quality healthcare to rural India Source: The Economic Times #healthcarestartupfundingindia #dseidehealthcarenetwork

MedVital, a MedTech startup focused on advanced wound healing and minimally invasive aesthetics, has raised Rs 8.4 crore in a pre-seed funding round led by Nihar Parikh’s 4point0 Health Ventures. The round also saw participation from prominent healthcare and logistics entrepreneurs, including the founders of Tata 1mg, NephroPlus, SafeExpress, Eye Q Hospital, Hexa Health, and AstroTalk. Amid rising cases of chronic wounds due to diabetes, obesity, trauma, and an increasing demand for non-invasive cosmetic treatments, MedVital is addressing a critical gap in accessible, outcome-driven skin repair and restoration technologies. Its flagship product, NoWound, is a compact, digitally enabled, and Made-in-India Negative Pressure Wound Therapy (NPWT) device designed for use in hospitals, clinics, and home-care settings, even in low-resource environments. "MedVital was founded on the belief that skin repair and restoration deserve the same level of innovation as any other medical field,” said Dr. Varun Gupta, Co-Founder and CEO. “We’re building a platform that combines clinically validated devices, intelligent monitoring, and biomaterials to treat complex wounds and restore patient confidence.” The funding will help MedVital expand its product portfolio, strengthen its supply chain, and extend distribution to tertiary hospitals, rural health centres, and home-based care. The company plans to launch liquid chitosan-based wound dressings and enter dermal and hair regeneration segments in the coming months. Co-Founder and COO Tarun Bansal stated, “Our goal is to position India as a global leader in advanced wound care. This funding fuels our mission to deliver practical solutions that work not just in ICUs, but across the entire healthcare ecosystem.” Investor Nihar Parikh added, “MedVital’s integrated approach to chronic wound care and aesthetics aligns with our vision of backing companies solving India’s healthcare challenges through innovation and impact. Their model combines clinical rigour with accessibility—a rare and powerful combination.” Source: bwhealthcareworld #healthcarestartupfundingindia #dseidehealthcarenetwork

Karan Bajaj, the founder of the edtech platform WhiteHat Jr., is back in the startup arena with a fresh venture—this time in healthcare. His new U.S.-based startup, Complement 1, has raised $16 million in a seed funding round to build a personalised, tech-enabled lifestyle coaching platform for cancer patients and individuals at high risk of developing the disease. The round, which was led by Owl Ventures and Blume Ventures, will help the startup scale its coaching infrastructure, enhance its AI-driven personalisation engine, and expand partnerships with cancer centres, health plans, and employers across the United States. It aims to integrate evidence-based interventions—ranging from nutrition and sleep to stress management and physical activity—into the cancer care pathway "Every oncologist will tell you patients need more support incorporating clinically recommended physical activity, nutrition and mind-body practices. We've cracked the code on daily engagement with personalised, compassionate coaching—helping patients make meaningful, lasting improvements during and beyond treatment." Offering one-on-one support Complement1, which is emerging from stealth mode, offers daily one-on-one support through "CoActive Coaches" who deliver customised guidance rooted in clinical research. According to the company, early trial data show that members report 37% fewer treatment side effects, 18% less pain, and 27% better sleep, with adherence rates exceeding 90%. The startup claims that its platform can reduce healthcare costs by up to 30% for cancer patients and high-risk individuals. "Most coaching models rely on a weekly check-in. We meet patients every single day,” said Trupti Mukker, Co-founder and COO of Complement 1. "That daily presence—powered by our CoActive Coaching method—is what creates the trust, accountability, and behaviour change that drive our clinical results. This funding allows us to scale that impact by investing further in our AI systems to ensure consistency, personalisation, and quality at scale. It’s a hybrid approach: high-tech infrastructure matched with high-touch delivery—designed specifically for the complexity of cancer care." "I've seen targeted lifestyle changes transform outcomes—from better energy to reducing recurrence risk," said Dr. Neil M. Iyengar, MD, a leading exercise-oncology researcher and board member of Complement 1. "The challenge has always been getting patients to implement those changes and stick with them. Complement 1's platform provides the intensive support patients need to make sustainable lifestyle shifts, with adherence rates I've never seen before in this field." Source: Indian Startup #healthcarestartupfundingindia #dseidehealthcarenetwork

Navneet Kaur is a prominent Indian entrepreneur and a leading advocate for women's health and empowerment. As the co-founder and CEO of FemTech India, she has been instrumental in transforming the landscape of women's healthcare in the country. Pioneering FemTech in India Under Kaur's leadership, FemTech India has emerged as the nation's first online repository dedicated to female health technology. The platform serves as a hub for founders, experts, and investors committed to revolutionizing women's health innovation in India. Kaur's vision is to make the femtech market, projected to surpass $100 million by 2025 and serve over 600 million women, both accessible and empowering . Advocacy and Policy Engagement Kaur's influence extends beyond entrepreneurship into policy and global advocacy. In 2023, she represented India at the MedFemTech Congress in Paris, discussing the burgeoning femtech landscape in the country. She also served as a Task Force Member during India's G20 presidency, participating in the G20-DIA Summit in Bengaluru, which focused on driving digital innovation for world economies . Her advisory role with the Department of Women and Child Development in Madhya Pradesh led to contributions to the Ladli Behna Yojana, a government initiative providing monthly sustenance to young women from underserved communities . Media and Community Engagement To foster dialogue and awareness around women's health, Kaur hosts "The FemTech India Podcast," featuring conversations with founders, doctors, public health professionals, policymakers, investors, and researchers. The podcast aims to provide clear, trustworthy information and challenge taboos surrounding women's health issues . Additionally, she launched "The FemTech Coffee Table Book," a first-of-its-kind project highlighting transformative endeavors in the femtech sector, market trends, and groundbreaking solutions. Her weekly newsletter, "FemTech Fridays," keeps subscribers informed about the latest developments in the FemTech ecosystem . Recognition and Impact Kaur's contributions have been recognized internationally. She received the "First in Femtech" award from the U.S.-based platform FemTech Focus, honoring individuals who demonstrate significant contributions to women's health innovation. FemTech India, under her leadership, was voted the best organization for women by an initiative launched by the Economic Times and Femina . Through her multifaceted efforts, Navneet Kaur continues to champion women's upliftment and advocate for affordable, accessible healthcare solutions, making a profound impact on the lives of women across India. Source: Startup News #healthcarestartup #dseidehealthcarenetwork

Miraqules, a medtech startup from Burdwan, is reengineering emergency bleeding control with StopBleed—a novel, fast-acting nano-biopolymer hemostat designed for hospitals, ambulances, and public use. In a country where road accidents claim nearly 700 lives a day—and excessive blood loss is often the cause—an emergency hemostat could mean the difference between life and death. Miraqules, a medtech startup, has developed StopBleed, a novel nano-biopolymer solution designed to control bleeding rapidly and effectively. The product, first conceptualized as a master’s thesis, is now the centerpiece of a mission to bring critical care closer to where trauma strikes—whether it’s a roadside crash, a battlefield, or a remote clinic. The Founder’s Journey: From Personal Crisis to Public Health Solution The story behind Miraqules is deeply personal. Founder Sabir Hossain grew up in a middle-class family in Burdwan, West Bengal. A traumatic childhood experience—watching his father bleed from an accident without access to proper first aid—left a lasting impression. Years later, while pursuing his master’s in Biomedical Engineering at NIT Rourkela, Sabir began working on biomaterials under Professor Devendra Verma. This academic pursuit soon evolved into a practical mission, culminating in the development of StopBleed. In 2018, Sabir co-founded Miraqules with Dr. Verma and his father. Dr. Mubeen Midda, a junior doctor in Delhi at the time, was drawn into the mission after seeing the product's potential firsthand. By March 2019, he joined full-time, bringing a clinical perspective that grounded the startup’s development in real-world needs. Addressing a Global Health Crisis Uncontrolled bleeding is a leading cause of preventable deaths globally, surpassing diseases like HIV and malaria. In India, roughly 30% of road accident deaths result from blood loss. Existing solutions like tourniquets and pressure dressings are often inadequate or situational. Miraqules(Miracle + Molecules) aims to bridge this gap with StopBleed, a first-response hemostat that is easy to use and effective across a range of settings—from ERs and ambulances to home first-aid kits. Inside the Technology: What Sets StopBleed Apart Unlike conventional hemostats, StopBleed mimics the body’s natural clotting process using a nano-biopolymer that forms fibrin-like threads. It features a 30x higher absorption rate, charge-based clotting acceleration, and atraumatic removal—crucial in emergency care. Designed in multiple formats (powder, gauze, pellets, and patches), the product is adaptable to various types of bleeding injuries, offering frontline responders and clinicians a powerful new tool in trauma management. Market Reach: From Battlefields to Backpacks Currently, Miraqules operates on a B2B and B2G model, planning to sell StopBleed in different formats priced between ₹300 and ₹5000. The long-term goal is to make StopBleed as common in first-aid kits as bandages, enabling bystanders to act before medical help arrives. The potential market is massive. Globally, over 700 million injuries occur annually, with more than 6 million deaths from blood loss. In India alone, 1500 road accidents happen daily. Yet hemostatic products remain scarce at the point of injury. Miraqules is looking to change that by offering a scalable, affordable solution. Achievements, Recognition, and Funding Over the past seven years, Miraqules has raised around $800,000 and secured patents in India, the U.S., and China. A pilot-scale manufacturing facility is in place, and the company is currently conducting human studies at St. John’s Hospital in Bangalore. Miraqules has received support from the Indian Council of Medical Research and won accolades such as the Startup MahaRathi Award and MassChallenge Israel Platinum Winner title. Their recent partnership with the Maharashtra Government will see StopBleed deployed in trauma centers and ambulances, reaching 800 patients as part of a paid pilot. Challenges and the Road Ahead Manufacturing scale-up remains the company’s biggest challenge. Regulatory hurdles and limitations in current bio-incubation facilities mean Miraqules will need to either raise capital to build its own facility or find strategic manufacturing partners. The immediate focus is on completing clinical trials and securing regulatory approvals from India’s CDSCO and the U.S. FDA. By 2026, the startup aims to ship 10,000 units, gain major public health adoption, and begin sales in the U.S. and Indian markets. Long-term goals include serving over 5 million patients and introducing 3–4 new wound care products to transform trauma and surgical care. A Mission Beyond Medicine Beyond saving lives, StopBleed promises to reduce hospital stays, lower transfusion rates, and ease healthcare costs—especially in resource-constrained settings. For Sabir and his team, the product isn’t just about science—it’s about giving people a fighting chance when every second counts. “Startups are consuming,” says Sabir. “Resilience will be more important than hard work. Be obsessed with the problem.” For him, Miraqules is more than a company—it’s a purpose forged from pain and shaped by persistence. Source: YourStory #healthcarestartupindia #dseidehealthcarenetwork

In a significant surge, Indian startups collectively raised approximately $585.71 million this week, marking a substantial increase from the $102.93 million secured the previous week. New Delhi: In a significant surge, Indian startups collectively raised approximately USD 585.71 million this week, marking a substantial increase from the USD 102.93 million secured the previous week. This uptick reflects a growing investor confidence and interest in India's burgeoning startup ecosystem. The majority of this funding was directed towards growth-stage companies, with notable investments including Porter, an on-demand goods transport agency, which secured USD 200 million in its Series F funding round. This round was led by Kedaara Capital and Wellington Management, propelling Porter into the unicorn club. Other significant growth-stage investments encompassed automotive company Routemotic, which raised USD 40 million in its Series C round, and interior design startup Flipspaces, which secured USD 35 million led by Iron Pillar. Additionally, logistics firm Celcius Logistics, foodtech company The Good Bug, and e-commerce startup Blissclub also attracted substantial investments this week. On the early-stage front, 20 startups collectively raised USD 263.41 million. Healthcare company PB Healthcare led this segment with an impressive USD 218 million seed round, backed by General Catalyst. Other early-stage startups that garnered funding include robotics company Posha, edtech firm Footprints, spacetech startup InspeCity, commercial vehicle platform 91Trucks, and proptech company Alt DRX. Geographically, Delhi-NCR-based startups led the funding race with 11 deals, closely followed by Bengaluru with 10 deals. Startups from Mumbai and Chennai also secured investments, indicating a diverse and widespread entrepreneurial activity across the country. Sector-wise, healthtech startups emerged as the most attractive to investors, securing four deals. Logistics and foodtech sectors followed with three deals each, while artificial intelligence, automotive, decor, and robotics sectors also saw investor interest. Meanwhile, in the previous week, the Indian startups had raised approximately USD 102.93 million across 25 deals, with strong contributions from early-stage and growth-stage companies. Bengaluru and Delhi-NCR-based startups led the funding race last week, with seven deals each, followed by Mumbai and Chennai. Source: Economic Times

Swiggy saw its losses almost double in Q4, dragged down by heavy spending on quick commerce. IntegriMedical is eliminating risks associated with traditional injections with its N-FIS technology. Saleswomentoring aims to help women to advance and thrive in sales. Business, it is said, is war without bullets. Amid the tense India-Pakistan conflict, investors are betting big on India’s military prowess, with some defence stocks seeing a double-digit surge on the bourses. Drone maker Ideaforge Technology’s shares hit the upper 20% circuit on Friday. Meanwhile, the shares of Bharat Dynamics, the manufacturer of ammunition and missile systems, rose 5.79% on the NSE as it ramps up production. The Indian financial ecosystem is erring on the side of caution. The Department of Financial Services has asked banks to strengthen their internal systems to deal with any cybersecurity threats, ensure uninterrupted services, and maintain enough cash in ATMs. Also, the Department for Promotion of Industry and Internal Trade has expanded the Credit Guarantee Scheme for Startups, doubling the guarantee cover limit to Rs 20 crore per borrower and increasing the guarantee coverage. From India’s financial landscape to the Vatican’s. The newly elected Pope Leo XIV has a big task ahead of cleaning up the Holy See’s finances, and he may as well use his degree in mathematics. ICYMI: When Pope Leo XIV visited India. Elsewhere, asset management firm Vanguard has pegged Ola parent’s valuation between $1.4-1.5 billion, trimming down the value of its holdings amid rising competition. In today’s newsletter, we will talk about. The cost of Swiggy’s growth Taking the pain out of healthcare Breaking glass ceilings in sales Here’s your trivia for today: Which movie holds the record for featuring the most number of extras? Quick Commerce The cost of Swiggy’s growth Food delivery and quick commerce platform Swiggy saw its losses almost double in the fourth quarter as heavy spending on quick commerce further dragged down the company’s bottom line. Swiggy Instamart, which competes with quick commerce unicorn Zepto and market leader Blinkit, more than doubled its operating revenue to Rs 689 crore, rising for the third consecutive quarter. However, the growth came at a cost, with the segment’s losses widening to Rs 770 crore from Rs 272 crore in the last year and Rs 527 in the previous quarter. Widening losses: Sriharsha Majety-led Swiggy saw its losses widen to Rs 1,081 crore from Rs 553.6 crore in the previous year. On a quarter-over-quarter basis, the company’s losses grew by 35% from Rs 799 crore. During the quarter, Swiggy’s Dineout business turned profitable with earnings of Rs 23 crore, an improvement from a loss of Rs 8 crore in the previous quarter. Additionally, the company is evaluating a potential shift to an inventory-led model for its quick commerce arm but is unlikely to make an inorganic move in the near term, according to group CFO Rahul Bothra. Source: YourStory #healthcarestartupindia #dseidehealthcarenetwork

Founded in 2020, IntegriMedical is a healthcare technology company on a mission to revolutionize drug delivery by eliminating the fear, discomfort, and safety risks associated with conventional needle-based injections. For millions across the globe, the sight of a needle is enough to induce anxiety, especially in children. Yet, needle-based injections remain the dominant method of drug delivery—even as safer, more comfortable alternatives have begun to emerge. But one Pune-based med-tech startup is working to take the dread out of necessary injections. Founded in 2020 by Sarvesh Mutha, Ankur Naik, Scott McFarland, and Mark Timm, IntegriMedical is on a mission to reimagine how medications are delivered. Their answer: a needle-free, spring-driven device that administers drugs through the skin using a high-pressure jet, minimizing trauma and eliminating the risks associated with traditional injections. Born from firsthand experience The idea for IntegriMedical was rooted in founder Sarvesh Mutha’s experience in the healthcare and medical device industries. “Needle phobia is more than just fear—it can cause patients to skip life-saving treatments,” says Mutha, now the company’s Managing Director. The issue also extends to healthcare workers, who are routinely exposed to needle-stick injuries and the risks of cross-contamination. Determined to develop a safer alternative, Mutha joined forces with co-founders Ankur Naik—an expert in device design and regulatory compliance; Scott McFarland—a healthcare veteran with deep experience in finance and delivery; and Mark Timm—a seasoned entrepreneur in global supply chain operations. “Together, we envisioned a future where drug delivery would be painless, sustainable, and more accessible,” says Mutha . Painless injection process The Needle-Free Injection System (N-FIS) is built around a stainless-steel piston mechanism that delivers medications intramuscularly or subcutaneously in under a tenth of a second. “Instead of a needle, the device uses a disposable cartridge with an orifice finer than a strand of human hair to create a precise jet stream. The result is a nearly painless experience that also reduces the risk of cross-contamination, tissue damage, and hazardous medical waste,” explains Mutha. The Pune-based startup received CDSCO approval for N-FIS in December 2022 and launched it commercially in April 2024 after pilot testing. The device is backed by regulatory approvals including CE, ISO 13485, and MDSAP, and is protected by a US patent. Source: YourStory #healthcarestartup #dseidehealthcarenetwork

A digital revolution is sweeping through the pharmaceutical industry, and it’s powered by artificial intelligence (AI). From automating drug discovery to making clinical trials more efficient and driving breakthroughs in biotechnology, AI is reshaping the healthcare landscape. And India, long known as the ‘pharmacy of the world, is positioning itself to ride this wave of innovation, as it should! India’s pharmaceutical sector has always been a global heavyweight. As the world’s third-largest producer of drugs by volume, it has historically focused on affordable generics. But now, with the infusion of AI-driven capabilities, the industry is shifting gears—becoming a hub of R&D, innovation, and precision medicine. As per a EY-Pantheon and Microsoft report that tracked the sector, AI market in pharmaceuticals is projected to hit USD16.49 billion by 2034 and AI-driven medical devices are set to grow to USD97.07 billion globally by 2028. India must move quickly and decisively to gain the necessary advantage and leverage. Major Indian pharmaceutical firms such as Sun Pharma, Dr Reddy’s Laboratories, and Cipla are investing heavily in AI technologies. Their goal: reduce the spiralling costs and timeframes associated with developing new drugs, and leapfrog into the realm of novel therapeutics. Meanwhile, India’s homegrown AI startups are gaining momentum by offering specialised solutions across the pharma value chain. Companies like Qure.ai, Indegene, and AIRA Matrix are helping digitise diagnostics, streamline clinical trial processes, and ensure regulatory compliance through advanced analytics and automation. Qure.ai, for example, has developed deep learning algorithms capable of interpreting complex medical images like X-rays and CT scans. These tools are not only helping doctors make faster and more accurate diagnoses but are also being integrated into clinical trial pipelines to identify suitable patient cohorts. Indegene, on the other hand, supports pharma companies in managing large datasets and enhancing patient engagement using AI-powered systems—bringing a new level of precision to the business side of medicine. Source: millenniumpost #healthcarestartup #india #dseidehealthcarenetwork

With policy backing and shifting global supply chains, India’s medtech industry is poised to emerge as a global manufacturing and innovation hub. India’s medtech industry is undergoing a dramatic transformation, propelled by shifting global trade dynamics, rising income levels, breakthrough innovations, and a renewed push for localisation. Once seen merely as a sales destination for global medtech giants, India is now positioning itself as a serious contender to become a global hub for innovation, manufacturing, and healthcare research. Driving this transformation is a confluence of factors: the cost competitiveness of Indian healthcare, a burgeoning middle class with growing health consciousness, the government’s production-linked incentive (PLI) scheme, and a policy push to develop a robust domestic medtech ecosystem. With rising domestic demand and a favourable business environment, India is attracting multinational players eager to tap into both its market and talent pool. India has become an increasingly attractive destination for global healthcare consumers, offering high-quality medical care at a fraction of the cost in developed countries. This cost arbitrage, along with a deep pool of skilled professionals and robust tertiary care infrastructure, has made India a magnet for medical tourism. Multinational corporations such as Siemens Healthineers and Philips are taking note. Siemens is investing Rs 91.9 crore in local manufacturing of advanced diagnostic imaging systems such as CT and MRI machines at its Bengaluru facility. Additionally, the company is building an integrated campus with a projected investment of Rs 1,910 crore. Philips, too, is doubling down on its ‘Make in India’ initiative, having invested around Rs 750 crore over recent years. Source: policy circle #healthcarestartupfunding #dseidehealthcarenetwork

InvAscent, a healthcare-focused private equity firm, has announced the final close of its fourth fund, India Life Sciences Fund IV (ILSF IV), at $305 million. Although this falls short of its initial target, the fund continues InvAscent's commitment to investing in India's life sciences sector. Strategic Investments from ILSF IV Since its inception, ILSF IV has been actively deploying capital across various segments of the healthcare industry: Maiva Pharma: In May 2024, InvAscent, in partnership with Morgan Stanley Private Equity Asia, invested INR 1,000 crore (~$120 million) in Maiva Pharma, India's second-largest pure-play injectables Contract Development and Manufacturing Organization (CDMO). The funds are earmarked for establishing a new manufacturing facility near Hosur, enhancing Maiva's capabilities in sterile dosage forms, including pre-filled syringes and oncology injectables. Geri Care Health Services: In January 2025, InvAscent led a ₹110 crore (~$13 million) funding round in Geri Care, India's pioneer in integrated geriatric care. The investment aims to expand Geri Care's services across key Southern Indian cities, including Bengaluru, Hyderabad, Kochi, and Coimbatore. ABI Health Technologies: In December 2023, InvAscent invested $10 million in ABI Health Technologies, a Bangalore-based health-tech SaaS company. ABI's flagship product, ClaimBook, automates hospitals' health insurance claims management processes and has been implemented in over 300 hospitals across India. InvAscent's Track Record Founded in 2005, InvAscent has established itself as a leading investor in India's life sciences sector. With assets under management exceeding $800 million, the firm has invested in over 35 companies across pharmaceuticals, healthcare delivery, medical devices, animal health, nutraceuticals, and healthtech industries. The successful close of ILSF IV, despite falling short of its target, underscores InvAscent's sustained commitment to fostering growth and innovation in India's healthcare landscape. Source: dealstreetasia #healthtechstartup #dseidehealthcarenetwork

Indian startups have recently secured approximately $103.2 million in funding, highlighting a robust interest from investors across various sectors. This influx of capital underscores the resilience and adaptability of India's startup ecosystem, even amidst global economic uncertainties. Key Funding Highlights Artificial Intelligence & Robotics: Pune-based AI and robotics startup Haber raised $38 million in a round led by Creaegis, with participation from Accel India and BeeNext Capital. This investment aims to advance AI-driven automation solutions, particularly in industrial automation—a sector ripe for disruption as companies seek efficiency and productivity gains. SaaS & Digital Health: Spry Therapeutics, a Pune-based SaaS company, secured $15 million in a round led by Flourish Ventures, with participation from existing investors Together Fund, Fidelity’s Eight Road Ventures, and F Prime Capital. The funding will accelerate Spry's growth in offering digital healthcare solutions, reflecting growing investor interest in tech solutions for healthcare. Biotech & Agritech: BioPrime, a biotech startup, raised $6 million in a round led by Belgium-based Edaphon. The funding, supported by existing investors Omnivore and Inflexor Ventures, will enable BioPrime to further develop its biotechnological solutions, particularly in agriculture and food security—two areas critical to addressing global sustainability challenges. Sectoral Trends The recent funding activities indicate a strategic shift towards sectors with long-term growth potential: Fintech: Continues to be a dominant sector, with significant investments reflecting the ongoing digital transformation in financial services. Enterprise Tech: Startups focusing on B2B solutions are attracting substantial funding, emphasizing the demand for innovative enterprise technologies. E-commerce: Despite a general slowdown, the sector remains active, with startups securing funds to enhance their platforms and customer reach. Outlook The infusion of $103.2 million into Indian startups signifies a positive trajectory for the country's innovation landscape. With investors showing confidence in sectors like AI, SaaS, biotech, and agritech, Indian startups are well-positioned to drive technological advancements and contribute significantly to the global market. Source: Munsif news #healthcarestartupfunding #dseidehealthcarenetwork

In an ecosystem where venture-backed direct-to-consumer (D2C) startups frequently chase scale at the expense of sustainability, Powerhouse91 has quietly emerged as a high-efficiency outlier. The roll-up e-commerce brand aggregator has crossed a major milestone: achieving INR 100 crore in annual recurring revenue (ARR) and turning EBITDA profitable as of April 2025, all with a modest USD 2.5 million (~INR 21.15 crore) in total funding. Founded in early 2022 by Aqib Mohammed and Shashwat Diesh, Powerhouse91 exemplifies a new wave of digital-first consumer brand builders focused on operational rigor, financial discipline, and category depth rather than blitzscaling. The company runs two core brands: Azah: A feminine hygiene and wellness brand. Slovic: Focused on fitness and lifestyle products. According to some reports, the startup processed approximately 2.4 lakh orders in March 2025 alone, predominantly via online channels including Blinkit, Zepto, and Amazon. Monthly order volumes continue to grow at a healthy double-digit rate, signaling robust consumer traction. EBITDA Breakthrough with Frugality at Core Powerhouse91’s path to profitability is particularly noteworthy in a funding environment where burn-heavy D2C models have faced increased investor scrutiny. While many roll-up startups raised large venture rounds in their early stages, Powerhouse91 has managed to scale sustainably with just USD 2.5 million from investors including Titan Capital, FJ Labs, Crossbeam Venture Partners, and Mamaearth’s co-founder Varun Alagh. The company has not raised funds in nearly four years. The company achieves EBITDA profitability by April 2025, despite posting a INR 4 crore EBITDA-level loss in FY25 and INR 5.97 crore in losses on INR 40 crore revenue in FY24. The turnaround demonstrates the startup’s strong margin improvement and cost-control efforts over the past year. Source: ipocentral #healthcarestartupfunding #dseidehealthcarenetwork

IIIT Bhopal Gets Govt Funding For AI Healthcare, Research Bhopal (Madhya Pradesh): Indian Institute of Information Technology (IIIT) Bhopal has secured four prestigious research projects under central government’s Partnerships for Accelerated Innovation and Research programme, administered by the Anusandhan National Research Foundation (ANRF). Working in association with IIT Indore as hub institution, IIIT Bhopal will contribute to national research initiatives in the critical domains of Healthcare and Medical Technology and Advanced Materials. The institute’s proposals were selected through a rigorous, multi-stage national evaluation conducted by ANRF at Indian Academy of Sciences, Bengaluru, on March 7-8, 2025. Source: Free Press Journal #healthcarefunding #dseidehealthcarenetwork

Care.fi, a healthcare-focused fintech startup, has raised Rs 6 crore in debt funding from RevX to deepen its involvement in the Ayushman Bharat scheme. The Gurugram-based startup plans to deploy the capital to strengthen its platform's ability to support hospitals participating in the rapidly expanding national health scheme. The funding comes as the Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB-PMJAY) broadens its reach. As of June 2024, the programme covers over 550 million beneficiaries and counts more than 29,000 empanelled hospitals, making it the world's largest health assurance initiative. Founded in 2021 by Sidak Singh and Vikrant Agrawal, Care.fi offers tech-enabled financial solutions to healthcare providers, including hospitals, doctors, and allied suppliers. The startup claims to have disbursed over Rs 800 crore to more than 100 healthcare institutions and has secured a Non-Banking Financial Company (NBFC) licence within just two years of operations. “Our focus has always been to ease the burden of operational and financial processes for healthcare providers," said Sidak Singh, Co-founder of Care.fi. "With the Ayushman Bharat scheme becoming more centralised and 60% of hospital revenue now coming from insurance schemes, our solutions can seamlessly plug into this evolving framework and help hospitals manage claims and cash flows more effectively.” Vikrant Agrawal, Co-founder of Care.fi, added, “This infusion from RevX will not only allow us to scale our operations but also enable better support for hospitals onboarded under the Ayushman Bharat initiative. We see this as a powerful step toward building a resilient and inclusive healthcare financing ecosystem in India.” Source: Indian startup news #healthcarestartup #startupnews #dseidehealthcarenetwork

Technology is reshaping healthcare in India, creating new opportunities for those interested in careers at the intersection of medicine, data, and innovation. From AI specialists to clinical analysts, a new wave of roles is e merging. The convergence of technology and healthcare is affecting how medicine is delivered in India. Healthcare is undergoing a major transformation, opening up diverse career opportunities for students and professionals interested in medicine, technology, and management. As healthcare systems evolve, new roles emerge at the intersection of clinical practice, research, data management, and technology, offering a wide range of options beyond traditional medical professions. 1. HEALTH INFORMATICS SPECIALIST Health informatics can be defined as the application of science and the art of data assessment and management concerning health information using digital tools. Health informatics specialists work with EHRs, patient information repositories, and analytics platforms to optimise care effectiveness. Hospitals, insurance companies, and health-tech startups need health informatics specialists to help integrate services and make sense of healthcare data. 2. BIOMEDICAL ENGINEER Biomedical engineering is primarily concerned with the design, manufacture, and maintenance of medical devices, and biomedical engineers in India are in high demand as the demand for low-cost, locally-made medical devices increases along with innovation in prosthetics, diagnostic devices, and complementary devices that detect human digital health. 3. CLINICAL DATA ANALYST Healthcare's digital transformation has produced massive amounts of health data. Clinical data analysts help organisations make sense of data to improve treatment for patients and workflow efficiency to enhance patient experience. They analyse trends, assess treatment performance, and support clinical trials. 4. DIGITAL HEALTH ENTREPRENEURSHIP Many professionals are forging their careers and embarking on entrepreneurial journeys by launching startups in the area of fitness applications, mental health platforms, or remote monitoring. India is making progress towards creating an ecosystem that supports digital health innovation through government policies like the National Digital Health Mission (NDHM). 5. AI AND MACHINE LEARNING SPECIALIST/HEALTHCARE Artificial intelligence is changing how we think about disease prediction, diagnosis and even drug discovery. AI and machine learning specialists are working in this niche to create algorithms to read X-rays, pathologists' slides, or predict risk in healthy individuals. Source: India Today #healthcarestartupfunding #startup #dseidehealthcarenetwork

PB Fintech, the parent company of Policybazaar and Paisabazaar, has made a significant investment of Rs 539.4 crore in its newly formed healthcare subsidiary, PB Healthcare Services Private Limited. The investment marks the first tranche of a larger seed funding round worth Rs 1,461.6 crore, which includes contributions from both PB Fintech and external investors. The funding was approved earlier through a shareholder postal ballot. The investment was completed on April 24 through the subscription of 5.39 crore Compulsory Convertible Preference Shares at Rs 100 per share. With this infusion, PB Fintech’s stake in the healthcare subsidiary will drop from 100% to 32.14% on a fully diluted basis. The strategic dilution is intended to attract external capital and includes the creation of an Employee Stock Option Plan to attract and retain top talent in the healthcare space. In a statement, PB Fintech emphasised that the investment is designed to strengthen PB Healthcare's financial foundation and support its ambitious growth goals. Establishing hospitals The subsidiary, incorporated in January 2025, plans to establish hospitals with a capacity of up to 1,000 beds in its first year, offering managed healthcare services tailored to Policybazaar's customer base. The move represents a significant diversification for PB Fintech, whose primary businesses have been in digital insurance and lending. The company sees healthcare as a natural extension of its services and a growing opportunity in India's underserved medical infrastructure landscape. PB Healthcare was established to operate in the healthcare and allied services space and is headquartered in Gurugram. It currently has an authorised capital of Rs 2,500 crore but has yet to report turnover, given its recent incorporation. Financial performance PB Fintech reported strong financial results in the December quarter of FY25, with revenue growing 48% year-on-year to Rs 1,292 crore and net profit rising to Rs 72 crore from Rs 37 crore a year ago. The healthcare investment is expected to build on this momentum and broaden the company's service ecosystem in the Indian market. Source: indianstartupnews #healthcarestartup #startupfunding #dseidehealthcarenetwork

​The Dubai Chamber of Commerce has inaugurated a new office in Bengaluru, underscoring its commitment to strengthening ties with India's technology and artificial intelligence (AI) sectors. This strategic expansion reflects Dubai's broader initiative to diversify its economy and establish itself as a global digital hub.​ Bengaluru: A Strategic Choice Bengaluru, often referred to as the "Silicon Valley of India," boasts a robust tech ecosystem. The city is home to over 2,000 IT companies and contributes more than one-third of India's total IT exports . Furthermore, it houses over 40% of India's Global Capability Centers (GCCs), making it a pivotal location for multinational corporations seeking innovation and technological advancement .​ Dubai's Vision for Digital Collaboration Dubai is actively transitioning from its traditional oil-based economy to a diversified digital economy. The emirate aims to double the digital economy's contribution to its GDP from 9.7% in 2022 to over 20% by 2031 . Initiatives like the Dubai AI Campus, the largest AI cluster in the Middle East and North Africa, exemplify this commitment .​ The UAE-India Comprehensive Economic Partnership Agreement (CEPA), effective since May 2022, further facilitates collaboration in emerging sectors such as AI, blockchain, and fintech . The new Bengaluru office is poised to serve as a conduit for Indian tech startups and enterprises aiming to tap into Dubai's burgeoning digital landscape.​ The establishment of the Dubai Chamber's office in Bengaluru offers Indian tech companies enhanced access to Dubai's resources, including funding opportunities and a supportive regulatory environment. This move is anticipated to foster increased collaboration, innovation, and growth for Indian enterprises in the global digital arena.​ For Indian tech entrepreneurs and startups, this development presents a significant opportunity to engage with Dubai's dynamic digital economy and expand their global footprint. Source: Deccan Herald #healthcarestartupnews #dseidehealthcarenetwork

Tulu Health, a pioneering healthtech and fintech startup founded by experts from AIIMS, IIT, and Stanford, has launched India’s first AI Agent Platform aimed at transforming patient experiences and streamlining hospital operations. Officially unveiled on April 12 at Pullman Aerocity, Delhi, the platform integrates modular AI agents with WhatsApp and hospital websites—making digital health services more accessible, personalised, and user-friendly. “Tailored for Hospitals, Built for Patients,” the platform is designed to eliminate friction in the healthcare journey. With support for multiple languages and mobile optimisation, it ensures that even users with low digital literacy can access AI-powered assistance without needing to download new apps. Dr. Adil, Founder of Tulu Health, said, “We built Tulu to meet patients where they are—on WhatsApp, in their language, with zero friction. This isn’t just a tool; it’s a transformation in how India experiences healthcare.” A former AIIMS doctor and Stanford India Biodesign fellow, Dr. Adil emphasised how Tulu addresses challenges like lack of care continuity, high out-of-pocket costs, and post-discharge gaps. This is his second healthtech venture, following a BIRAC-funded startup incubated at IIT Delhi. Tulu’s platform supports hospitals by expanding patient reach, enhancing care flow, and automating workflows through white-labeled AI agents that plug into systems like EHR, CRM, ERP, and WhatsApp. Patients benefit from AI-assisted decision-making, cashless support for pre- and post-hospitalisation (up to 180 days), and real-time access to financial options. Advanced tech—such as generative AI, NLP, and deep learning—powers the solution, developed in-house with support from global partners like OpenAI and Anthropic. Dr. Vijay Agarwal, President of the Consortium of Accredited Healthcare Organisations, praised Tulu’s AI-driven pre-surgery consent and education tools, saying, “Tulu represents a great hope for the future of healthcare: collaborative, compassionate, and innovative.” Akif, Advisor to Tulu Health and ex-Innovaccer leader, added, “Tulu’s AI agents offer human-centered design at scale. The monetisation model through hospital-linked marketplaces is a breakthrough.” Tulu Health is onboarding hospital networks, state governments, and NBFCs for pilot projects. It’s also in discussions with leading public health bodies like AIIMS, GTB Hospital, and LNJP for broader rollout. With a B2B2C model, SaaS subscriptions, and transaction-linked revenue streams, Tulu aims to become a global AI agent marketplace. The startup is well-positioned to lead India’s push into Agentic AI, with Deloitte reporting that 80 per cent of businesses are exploring autonomous agent solutions. Source: bwhealthcareworld #healthcarestartup #AI

The India Artificial Intelligence market has experienced tremendous growth in recent years, positioning itself as a global leader in artificial intelligence (AI) innovation and adoption. With advancements in smart technology solutions, AI is now reshaping industries such as healthcare, finance, education, and more. This transformative shift is driven by the increasing availability of big data, improvements in computational power, and a growing ecosystem of startups and tech companies pushing the boundaries of AI capabilities. India is quickly emerging as a hub for AI development due to its unique combination of technological prowess, a large talent pool, and a booming startup ecosystem. The AI market in India is expected to witness significant expansion, providing vast opportunities for businesses to enhance operations, improve efficiency, and drive innovation. Artificial intelligence has brought about notable changes in India's healthcare sector, enhancing patient care and improving the efficiency of medical services. AI-powered systems are helping medical professionals in diagnosing diseases more accurately, recommending treatment plans, and predicting patient outcomes with advanced data analytics. These AI solutions in healthcare are enabling faster decision-making, reducing errors, and optimizing hospital management. A prime example of AI's role in healthcare is its application in medical imaging and diagnostics. AI algorithms analyze medical images, such as X-rays, CT scans, and MRIs, to detect signs of diseases like cancer or neurological disorders. This can lead to earlier detection, which is crucial for improving patient outcomes. Moreover, AI is playing a pivotal role in personalized medicine. By analyzing a patient's genetic data, AI can recommend personalized treatment options, ensuring better results. In a country like India, where there is a large population with diverse medical needs, AI's role in healthcare transformation is undeniable. The financial sector in India is also experiencing significant changes due to the integration of AI technologies. Financial institutions are leveraging AI to streamline operations, enhance customer experience, and improve decision-making processes. AI-powered tools enable banks and insurance companies to automate repetitive tasks, reduce human error, and make more accurate predictions regarding credit risk and investment strategies. Source: tech.einnews #healthcarestartup #AI #healthtech

AI-driven innovations in health are poised to become more significant in healthcare and fields such as cell and gene therapy, affordable care, and maternal, newborn, and child health (MNCH) are to see significant improvements, according to Taslimarif Saiyed, Director and CEO, Centre for Cellular and Molecular Platforms (C-CAMP). According to the Ministry of Ayush, GOI, 2025, the Indian healthcare sector is expected to reach USD 638 billion from USD 110 billion in 2016 due to rising income levels, greater health awareness, increased precedence of lifestyle diseases, and improved access to insurance, which would be the key contributors to growth. C-CAMP has received tremendous support from the government to spur innovations over the years, said Saiyed, and he added that bodies such as the Department of Biotechnology, Niti Ayog, BioBank, the Karnataka Government, and the Centre have been backers of the project. "The support is largely allowing us to build and take, I would say, take risk with such ideas. There's a lot of risk involved because there are new ideas. So we take the role of practitioners on the ground and get resources from the government to identify the talent, attract them, and then hand-hold them for many years till they become successful like that. So that's why the support from the government is very important because when a market doesn't take risk, the government has to take the risk. That's the role of government, and it has been able to to do it," Saiyed told Entrepreneur India. Startup innovations, especially in the healthcare sector has seen significant growth, with healthtech startups reportedly raking in USD 7.25 billion in funding between 2014 and 2024 according to an Inc42 Funding Report. C-CAMP today hosted and mediated a bilateral discussion between the Karnataka Government represented by Dinesh Gundu Rao, Minister of Health and Family Welfare, and Barbara Goezinne, Dutch Vice Minister of Health, Curative Care. Discussions took place around a possible Indo-Dutch partnership to focus on digital health and AI-powered healthtech from the state. "Innovation should be translated into real-world applications and C-CAMP has been playing a crucial role. Several innovations from C-CAMP have already been implemented, such as solutions for eye care and retinopathy treatment. Another example is technology to measure fetal heart rate in the womb. It is great to have visitors from the Netherlands here today—we can learn from experiences and explore potential collaborations in the future," said Gundu Rao. During the meeting, the Dutch delegation expressed interest in finding paths to develop selected advanced Karnataka-based healthcare technology in the Netherlands around scopes such as labor-saving technologies in healthcare, innovations in pharmaceuticals with AI in drug development and discovery, and remote monitoring and telehealth-related solutions as a screening method. Barbara Goezinne said, "The philosophy to make innovative technologies, like stem cell therapy, more accessible and affordable is really inspiring. We are committed to working together in the field of medical technology, particularly in the development of innovative, labour-saving medical solutions to support all health care professionals." C-CAMP's existing portfolio includes more than 80 deeptech startups covering areas such as Artificial Intelligence (AI) and Machine Learning (ML), genomic data analysis, healthcare analytics/big data, computer-assisted diagnosis, Internet of Things (IoT), Virtual & Augmented Reality, wearables, and other similar technologies "We have a strong cohort of AI-based health tech startups that have impact potential not only for resource-poor settings but also the Global North where resources are aplenty but healthcare challenges and economic burden of health persist," added Saiyed. Source: Entrepreneur India #healthcarestartup #dseidehealthcarenetwork

New Delhi: Care.fi, a pioneering healthcare-focused fintech startup, has secured INR 7.5 Cr in debt capital from Vivriti Capital to accelerate its mission of revolutionizing Revenue Cycle Management (RCM) for hospitals. With a strong emphasis on claims processing and financial automation, this funding will further expand the reach of RevNow by Care.fi, India’s most advanced AI-powered RCM platform designed to optimize hospital insurance claims and streamline revenue realization. This latest investment follows Care.fi’s previous funding rounds, which included INR 8 Cr in debt capital raised from Wint Wealth (Ambium Finserve) and Caspian, along with $2.5 Mn (around INR 21 Cr) in debt from Trifecta Capital and UC Inclusive Credit. In total, the group has raised approximately INR 29 Cr to date. In India’s evolving healthcare ecosystem, managing insurance claims remains a complex challenge for hospitals, often leading to delayed discharges, revenue leakages, and operational inefficiencies. Care.fi has revolutionized hospital claims processing, handling over INR 800 Cr in claims across 300+ hospitals and auditing more than 50,000 claims. Its AI-driven RCM platform, RevNow, is making a significant impact by expediting claim settlements and ensuring hospitals receive payments within 3-5 days post-discharge. It enables 30-minute patient discharges by automating final billing and approvals, drastically reducing wait times. RevNow optimizes hospital workflows with real-time query notifications, automated responses, and integrated mailing services. It also enhances financial transparency by providing real-time reconciliation of cash flows at the entity, unit, and claim levels, offering hospitals unparalleled visibility. Sidak Singh, co-founder of Care.fi, shared, “Since our inception, we have focused on solving critical operational pain points in hospital revenue management. With RevNow, we are setting new benchmarks in claims processing efficiency. This latest funding will enable us to scale further, helping hospitals optimize financial workflows while ensuring better patient experiences. As the healthcare ecosystem grows, we aim to continue innovating and improving revenue realization for providers.” With its latest funding round, Care.fi aims to expand RevNow’s capabilities and integrate further with hospital information systems (HIS), electronic health records (EHR), and billing platforms. The company is also focused on talent acquisition to strengthen its team and further drive innovation in RCM. “Our primary focus is to enhance the reach and effectiveness of our claims processing solutions,” said Vikrant Agrawal, co-founder of Care.fi. “We have already facilitated insurance claims for over 50,000 patients, and this funding will enable us to further expand our presence in the healthcare sector, bringing more hospitals into the fold and improving financial efficiency across the industry.” With an ambitious vision to become a 10 Billion Dollar enterprise by 2030, Care.fi is redefining healthcare finance by bridging gaps in insurance claims processing, ensuring financial stability for hospitals, and enhancing the overall patient experience. Source: APN NEWS #healthcarestartupindia #dseidehealthcarenetwork

​Navina, an AI-powered clinical intelligence platform, has successfully secured $55 million in a Series C funding round led by Growth Equity at Goldman Sachs Alternatives, with participation from existing investors Vertex Ventures Israel, Grove Ventures, and ALIVE. This latest investment brings Navina's total funding to $100 million. ​ Founded in 2018, Navina integrates artificial intelligence with electronic health record (EHR) systems to provide clinical insights, flag potential diagnoses, identify risk factors, and detect medication conflicts. The platform is currently utilized by over 1,300 clinics in the United States, aiming to enhance care quality and patient outcomes by efficiently managing and analyzing patient data. ​ The newly acquired funds will be used to accelerate Navina's expansion across the U.S. healthcare market, enhance its proprietary AI technology, and further drive improvements in patient outcomes by bringing proactive clinical intelligence to every outpatient interaction. ​ Navina plans to use the new funding to enhance its offerings, including developing ambient scribing capabilities for full documentation support. While not yet profitable, CEO Ronen Lavi aims for profitability within the next two to three years. ​ Navina's competitive edge lies in its alignment with clinics' financial needs and a strong provider experience, setting it apart in a competitive market of AI in healthcare data analysis. Source: TechinAsia #healthcarestartupindia #dseidehealthcarenetwork

Since its emergence on the life sciences stage, some of the best use cases of artificial intelligence (AI) have been the creation of indispensable tools for drug discovery, patient engagement, and healthcare operations. However, the biggest opportunity for AI right now is to develop treatments for rare diseases that still have no effective therapies. Shikha Singhal, principal of data science at Axtria, discussed the AI-driven future of the life sciences industry with AIM. “With less than 5% of 7,000 known genetic diseases having treatments, pharma companies will prioritise niche therapies, supported by AI-enabled patient analytics and real-world data,” she said. In 2024, Demis Hassabis and John M. Jumper were awarded the Nobel Prize in Chemistry for their contributions to AI-assisted protein structure prediction. Shikha believes these advancements set the stage for 2025, which promises even greater strides in efficiency and effectiveness, patient engagement, and innovative therapies. As the industry builds on this momentum, Shikha outlined several key trends that will enhance drug lifecycle management. “AI is centre stage right now and pharma is figuring out the ideal human-AI combination, reinventing their business functions with new ways of working,” shikha said. She added that AI and advanced analytics are key to developing tailored medicine, AI-powered cloud solutions enable instant data-driven decisions, and how highly personalised treatments are a reality thanks to the use of digital twins. Shikha says Axtria is leading the charge with AI-based products and services that make digital transformations successful, paving the way for these exciting treatment innovations. Source: analyticsindiamag #healthcarestartupindia #dseidehealthcarenetwork

​After decades of persistent advocacy and struggle, Mumbai's Mankhurd area is set to receive a 410-bed multi-speciality hospital in Lallubhai Compound, a significant development for a community that has long been deprived of adequate healthcare facilities. ​ Lallubhai Compound houses over 45,000 residents, many of whom were relocated from various parts of Mumbai in the early 2000s due to infrastructure projects. Despite this substantial population, the area has historically lacked essential amenities, particularly in healthcare. A 2018 study by Doctors for You revealed that 8-10% of households in the vicinity had at least one member suffering from tuberculosis, underscoring the pressing need for medical services. ​ The new hospital, constructed by the Mumbai Metropolitan Region Development Authority (MMRDA), comprises two ground-plus-nine-floor buildings and an eight-story staff quarters. The facility is slated to be handed over to the Brihanmumbai Municipal Corporation (BMC) in September, nearly a decade after its initial proposal. Currently, the buildings remain unoccupied as the BMC has recently floated a tender inviting bids to operate the hospital under a public-private partnership model. The deadline for bid submission is March 27, after which it will take a few months to commence outpatient services and approximately a year to begin surgical operations. ​ Residents have long faced challenges due to the absence of nearby quality healthcare facilities. The closest option, Shatabdi Hospital in Shivaji Nagar, is often bypassed in favor of Rajawadi Hospital, located 5 kilometers away, or other city hospitals perceived to offer better care. This situation has led to delays in treatment and additional hardships for patients and their families. ​ The establishment of this hospital is the culmination of years of persistent efforts by the community, who engaged with local corporators, Members of the Legislative Assembly (MLAs), and Members of Parliament (MPs) to advocate for improved civic amenities, with healthcare being a primary focus. The realization of this project marks a significant milestone in addressing the healthcare needs of Mankhurd's residents and exemplifies the impact of sustained community activism. Source: The Times of India #healthcarestartup #dseidehealthcarenetwork

In a landmark achievement for India's biotech sector and cancer treatment, Delhi-based startup Cellogen Therapeutics has received regulatory approval for the world’s first indigenous Bi-Specific 3rd Generation Chimeric Antigen Receptor T (CAR T) cells. This breakthrough places India at the forefront of advanced cell and gene therapies, offering new hope for patients battling blood cancers. India ranks third globally in cancer incidence, after the United States and China, with blood cancers accounting for 8 per cent of all newly diagnosed cases. According to the GLOBOCAN report, leukaemia, lymphoma, and multiple myeloma affect thousands of patients in India, including around 30,000 children annually. Cellogen Therapeutics’ bi-specific CAR T platform represents a transformative advancement in cancer immunotherapy. Unlike conventional CAR T therapies that target a single antigen, this innovation engages two tumour-specific antigens simultaneously, improving treatment precision while reducing side effects such as cytokine release syndrome and neurotoxicity. "This approval is a testament to India’s growing expertise in cutting-edge biotechnology and precision medicine," said Dr. Gaurav Kharya, founder of Cellogen Therapeutics. “Developing this CAR T product required three years of relentless research. Our goal has always been to create world-class therapies that are both accessible and affordable, and this innovation brings us closer to that vision.” This development aligns with the Atmanirbhar Bharat (self-reliant India) initiative, reinforcing India’s ability to drive medical innovation. CAR T therapy has traditionally been dominated by Western countries, with treatment costs exceeding USD 400,000. However, Cellogen’s technology is expected to reduce these costs by over 90 per cent, making life-saving therapies more accessible, especially in low- and middle-income countries. Cellogen Therapeutics has received $2 million in funding from NATCO Pharma, which has acquired a 5.38 per cent stake in the company. The startup is set to begin clinical trials in collaboration with Christian Medical College (CMC), Vellore, evaluating the safety and efficacy of the therapy. Dr. Tanveer Ahmad, lead researcher and CAR T cell therapy expert emphasised the impact of this innovation, “Our Bi-Specific 3rd Generation CAR T platform is the result of years of rigorous research and state-of-the-art cell engineering. This therapy offers a highly targeted and durable treatment option, significantly improving patient outcomes.” The research is backed by leading institutions, including the Council of Scientific & Industrial Research (CSIR), the Regional Centre for Biotechnology, the Institute of Genomics and Integrative Biology, and NATCO Pharma. With this approval, Cellogen Therapeutics is set to redefine cancer treatment, making CAR T therapy more effective, affordable, and accessible for Indian and global patients. Source: Healthcare World #healthcarestartupindia #dseidehealthcarenetwork

Zeno Health has launched a 50-minute medicine delivery service in India after raising US$25 million in its series C funding round. The healthtech startup operates over 180 retail pharmacy stores across Maharashtra, India, integrated with a tech-enabled logistics network. Customers can order medicines via its mobile app, in-store, or by phone, with no minimum order or delivery fee. Founded in 2017, Zeno Health focuses on affordable generic medicines by sourcing directly from manufacturers. It also runs 200 micro-franchises in Maharashtra and West Bengal, serving over 1.5 million customers. The company has raised over US$56 million from investors like STIC Investments and Lightbox, aiming to expand operations and enhance its technology. The 50-minute delivery service taps into the growing demand for rapid healthcare delivery. Competitors like Tata 1mg, Netmeds, PharmEasy, and Flipkart Health+ are active in this space. New players such as Plazza and quick commerce platforms like Flipkart Minutes and Swiggy Instamart are also exploring opportunities. Source: TechInAsia #healthcarestartupindia #dseidehealthcarenetwork

Sarvam AI, founded in 2023 by Dr. Vivek Raghavan and Dr. Pratyush Kumar, is a Bengaluru-based startup pioneering India's first homegrown generative AI tailored for the country's diverse linguistic landscape. The company focuses on developing large language models (LLMs) that support multiple Indian languages, aiming to make AI accessible and practical for all. In December 2023, Sarvam AI secured a $41 million Series A funding round led by Lightspeed, with participation from Peak XV Partners and Khosla Ventures. This investment underscores the company's potential to create AI applications at a population scale, specifically designed for India's multilingual environment. By October 2024, Sarvam AI launched Sarvam-1, a homegrown LLM with approximately two billion parameters, supporting 10 major Indian languages, including Bengali, Marathi, Tamil, and Telugu. Built using NVIDIA's H100 Tensor Core GPUs, Sarvam-1 claims to outperform standard benchmarks while achieving high accuracy in both knowledge and reasoning tasks, particularly in Indic languages. In February 2024, Sarvam AI collaborated with Microsoft to make its Indic voice LLM available on Azure. This partnership leverages Azure's AI infrastructure to build and deploy voice-enabled generative AI applications, aiming to empower enterprises to adopt AI solutions quickly and responsibly. Sarvam AI's commitment to advancing AI adoption in India is further demonstrated by its development of Sarvam 1, a 2-billion-parameter multilingual LLM supporting 11 languages: Bengali, Gujarati, Hindi, Marathi, Malayalam, Kannada, Oriya, Tamil, Telugu, Punjabi, and English. Built entirely on NVIDIA technology, Sarvam 1 is designed to power a range of applications, including voice and messaging agents, and is available as an open-source model for developers to build their own generative AI applications for Indic language speakers. Through these initiatives, Sarvam AI is positioning itself as a leader in developing AI solutions that cater to India's unique linguistic and cultural diversity, contributing significantly to the country's AI ecosystem. India Is Emerging as a Key Player in the Global AI Race Source: Business Today #healthcarestartup #AI #dseidehealthcarenetwork

Founded in 2024 by Harshit Kukreja and Akash Kumar, Raaz offers personalised, evidence-based male reproductive treatment for conditions like erectile dysfunction and premature ejaculation. Men’s reproductive health remains a largely taboo subject in India, with millions suffering in silence from conditions such as erectile dysfunction, premature ejaculation, testosterone deficiency, and sperm count issues. While conversations around women’s health have gained momentum, male reproductive health continues to be overlooked, leaving many without access to proper diagnosis or treatment. According to the Indian Society for Assisted Reproduction, nearly 15% of Indian couples face infertility issues, with male factors contributing to almost 50% of cases. A study by the Indian Journal of Urology further reveals that nearly one in four men experience sexual dysfunction, yet only a small fraction seek professional help due to stigma and misinformation. Addressing this gap, Raaz, a Delhi-based startup, offers discreet, accessible, and medically backed solutions for male reproductive health. Source: Your Story #healthcarestartupindia #startupfunding #dseidehealthcarenetwork

The International Finance Corporation (IFC), a member of the World Bank Group, has proposed an equity investment of up to $35 million, with an additional co-investment envelope of up to $30 million, into A91 Partners' third fund. This new fund aims to raise $675 million in total commitments, marking A91's largest fund to date. A91 Partners, established in 2018, focuses on providing capital to small and mid-market companies across sectors such as consumer, financial services, healthcare, manufacturing, and technology. The third fund is expected to invest between $10 million to $50 million in approximately 15 companies. The firm has shown significant growth in its fundraising efforts: First fund (2018): $350 million Second fund: $550 million Third fund (current target): $675 million A91's investment portfolio includes companies like Akshayakalpa (dairy products), Blue Tokai (specialty coffee), and Sugar (beauty and personal care). Additionally, their portfolio company, Go Digit General Insurance, went public last year. This proposed investment by IFC reflects a growing interest in Indian venture capital firms, with others like Accel and Bessemer Venture Partners also raising substantial India-focused funds recently. Source: Your Story #healthcarefundingindia #dseidehealthcarenetwork

India is taking a major step towards pharmaceutical innovation by launching a ₹5,000 crore Research & Development (R&D) fund to boost drug discovery and medical research. The initiative aims to position India as a global leader in pharmaceuticals by encouraging research in novel drug formulations, biologics, and cutting-edge healthcare technologies. The fund will provide financial support to pharmaceutical companies, startups, and research institutions, fostering innovation in critical areas such as oncology, rare diseases, and precision medicine. This move aligns with the government's vision of strengthening the "Make in India" and "Atmanirbhar Bharat" initiatives, reducing dependency on imports and enhancing self-sufficiency in life-saving drugs. With India's pharma sector projected to reach $130 billion by 2030, this investment in R&D is expected to drive groundbreaking advancements, attract global collaborations, and create new job opportunities. Experts believe that with increased funding, India can bridge the gap between generic drug production and high-end pharmaceutical innovation, further solidifying its position as the "Pharmacy of the World." This strategic push for innovation marks a transformative era for India's pharmaceutical and healthcare ecosystem. #PharmaInnovation #MakeInIndia #AtmanirbharBharat #HealthcareResearch #BiotechIndia #MedTech #PharmaR&D #DrugDiscovery #HealthcareInnovation #Dseidehealthcarenetwork Source: IndiaMed Today

Bessemer Venture Partners has raised $350 million for its second dedicated India fund, reaffirming its commitment to supporting India's thriving startup ecosystem. Here's a breakdown of what the new fund means for entrepreneurs: Key Focus Areas of the New Fund AI, SaaS, Fintech, and More: The fund will target early-stage investments across industries like AI-enabled services, SaaS, fintech, digital health, consumer products, and cybersecurity. Supporting Growth: While focused on early-stage startups, Bessemer will also back companies through subsequent growth stages to scale effectively. A Long-Term Commitment to India Bessemer’s presence in India dates back nearly 20 years, during which time the firm has invested in over 80 startups. With this new fund, the firm reaffirms its dedication to partnering with founders early and supporting them long-term. Insights from Bessemer Leadership Vishal Gupta, Partner and Managing Director of Bessemer's Bangalore office emphasized the firm's ongoing focus: “This fund deepens our commitment to India’s startup ecosystem as we continue backing the next generation of entrepreneurs building technology-led businesses.” He added, “We remain focused on identifying and investing in founders who are driving innovation, solving complex challenges, and building market-defining companies. Beyond providing capital, we bring deep sector expertise, a global network, and hands-on support to help founders navigate their growth journeys and scale sustainably.” Anant Vidur Puri, Bessemer Partner, highlighted India's role in the AI revolution: "India is at the forefront of the AI-driven transformation, with founders building domestic as well as globally competitive businesses across enterprise software, fintech, and consumer technology." Bessemer has consistently invested early in key market shifts, including the mobile revolution, India’s digital infrastructure, and the healthcare revolution. Notable investments include Urban Company, Perfios, and Medi Assist. The first India fund also backed successful startups like Boldfit, MoveInSync, and Pepper Content. With a globally integrated team, Bessemer is committed to supporting innovation and fostering the next generation of leaders in India’s digital economy. The new fund positions them well to continue nurturing the future of tech in India. Source: Ciol #healthcarestartupfunding #startupfunding #dseidehealthcarenetwork

Allo Health, a pioneering sexual wellness startup, has secured ₹16 crore in a pre-Series A funding round led by Zerodha's Rainmatter, with participation from existing investors. This investment marks a significant milestone in Allo's mission to revolutionize India's sexual health landscape by expanding its clinic network, enhancing AI-driven treatment protocols, and improving patient engagement. Founded by Pranay Jivrajka, Allo Health operates over 35 clinics across major cities like Bangalore, Mumbai, and Hyderabad, treating over 200,000 patients with an impressive 85% improvement in outcomes. The startup's hybrid model combines physical clinics with AI-powered treatments and expert-led care, addressing the long-standing stigma and accessibility issues in sexual health. Beyond sexual health, Allo plans to expand into mental health, leveraging its structured and patient-first approach. The company aims to invest in diagnostics, digital therapy, and private-label solutions to strengthen its healthcare ecosystem. This funding validates Allo's vision to transform healthcare in India by focusing on patient outcomes and evidence-based care. As Allo continues to grow, it is poised to redefine how sexual and mental health services are delivered across the country. #AlloHealth #SexualHealth #MentalHealth #HealthcareInnovation #Rainmatter #Zerodha #HealthTech #IndiaHealthcare #PatientFirstApproach #HealthcareEcosystem #Dseidehealthcarenetwork Source: APN News

Adult immunization is essential in preventing infectious diseases such as influenza, hepatitis B, pneumococcal infections, and cervical cancer. However, in India, it remains largely neglected due to several factors, including low awareness, lack of structured policies, and the misconception that vaccines are only for children. Unlike childhood immunization, which is well-integrated into public health programs, adult vaccination is not widely promoted. Many healthcare providers do not actively recommend vaccines for adults, leading to a lack of motivation among the general population. Another major barrier is cost. Since most adult vaccines are not covered under government-funded programs, individuals must pay out-of-pocket, making them less accessible. Additionally, cultural beliefs and misinformation contribute to vaccine hesitancy. With an aging population and increasing prevalence of lifestyle diseases, prioritizing adult immunization can significantly reduce healthcare costs, hospitalizations, and mortality rates. Strengthening policies, integrating vaccinations into routine health check-ups, and launching public awareness campaigns can help improve immunization rates among adults in India. #AdultImmunization #VaccinationAwareness #PreventiveHealthcare #PublicHealthIndia #StayProtected #ImmunizationMatters #HealthyIndia #DiseasePrevention #Dseidehealthcarenetwork Source: The Hindu

Bengaluru-based health startup Allo Health has raised 16 crore rupee (US$1.83 million) in a pre-series A funding round led by Rainmatter, with participation from existing investors. The funds will be used to expand its clinic network, enhance AI-driven treatment frameworks, and develop patient-focused innovations. Allo Health operates over 35 clinics across India, including in Bangalore, Mumbai, Hyderabad, and Pune. Since its launch, the company has treated more than 200,000 patients. This funding follows a US$4.4 million seed round led by Nexus Venture Partners, with investments from Flipkart co-founder Binny Bansal and Zomato founder Deepinder Goyal. The startup continues to pursue a hybrid healthcare model, combining physical clinics with technology-driven treatment approaches. Source: Tech in Asia #healthtechstartup #startupfunding #dseidehealthcarenetwork

What makes AstraAI Special? Checkout the products released in the market place !

Zydus Lifesciences is set to acquire a significant stake in French medtech company Amplitude for ₹2,446 crore, marking a strategic expansion into the global orthopedic implant market. Amplitude, known for its innovative solutions in joint reconstruction and orthopedic surgery, aligns with Zydus’ vision to strengthen its medical technology portfolio. This acquisition will enhance Zydus’ presence in the European market while leveraging Amplitude’s expertise in high-performance orthopedic devices. The move signifies Zydus’ commitment to advancing healthcare solutions and broadening its footprint beyond pharmaceuticals. With the global orthopedic market growing rapidly, this deal positions Zydus as a key player in medtech innovation. The acquisition is expected to drive synergies between both companies, fostering research and development in next-gen orthopedic solutions. #Zydus #Amplitude #MedTech #HealthcareInnovation #Orthopedics #MedicalDevices #HealthcareExpansion #GlobalHealthcare #ZydusLifesciences #HealthcareTech #Dseidehealthcarenetwork Source: The Economic Times

Founded in 2019 by Chris George and Gagan Kapur, Mumbai-headquartered QubeHealth ensures employees have immediate access to medical funds. It serves over 300 companies, covering about 1.5 lakh employees and their families. How much are you paying for health insurance premiums? A lot in recent years. In fact, many costs, including diagnostics and consultations, remain uncovered for those availing of employer-provided health insurance; not to mention the extra hospital expenses one pays out of their pocket. According to the Acko India Health Insurance Index 2024, healthcare costs in India are rising at an annual rate of 14%, with 62% of hospital expenses paid out of pocket and 23% covered through borrowings. Further, increased demand for advanced treatments and a higher incidence of chronic diseases among Indians have shot up medical inflation and insurance premiums in the country. A study by Policybazaar.com found that while most customers saw renewal premium hikes of under 10%, nearly 5% experienced increases of over 30%, with some premiums rising to 200% over the last decade—forcing many to liquidate their savings or assets to afford medical care. “While corporate insurance penetration is high, employees still struggle with everyday c that are either uncovered or require cumbersome reimbursements,” Chris George, Co-founder and CEO of QubeHealth, tells , Recognising this challenge, George and Gagan Kapur launched QubeHealth in 2019 to ensure employees have immediate access to medical funds by integrating UPI-based payments, no-cost financing, and embedded insurance into employee benefits. “Our goal was to create a platform that provides instant access to funds for seamless medical payments,” he says, adding the Mumbai-based B2B healthcare payments startup has a team of about 12 employees. George, an MBA from NYU-Stern, had earlier launched an ecommerce venture EasyBuyMusic/EasyBuyStore, backed by ICICI Ventures, and later EBS Worldwide, a tech-driven marketing services group, before starting QubeHealth. Kapur, his acquaintance of 25 years, served as the Country Head for Argonaut Private Equity and spent over a decade at EY. Source: Your story #healthcarestartupfunding #fundingindia #dseidehealthcarenetwork

A recent survey by a health-tech platform reveals that 60% of gynecology appointments in 2024 were sought by women aged 25-34, indicating a rising focus on reproductive and hormonal health. Gynecology accounted for 19% of all consultations by women, surpassing general physician visits, highlighting a growing awareness of women's healthcare needs. The report shows that young women are increasingly seeking medical advice for conditions like PCOS/PCOD, irregular menstrual cycles, fertility concerns, breast health, and abortion-related queries. Mental health is also emerging as a priority, with increased consultations for marriage counseling and individual therapy. Geographically, tier-1 cities dominated the gynecology consultation trends, accounting for 76% of total appointments. Delhi NCR led the way with 33%, followed by Bengaluru at 28% and Mumbai at 12%. This suggests that urban women are more proactive about seeking medical guidance, aided by digital health platforms that offer accessibility and convenience. With increasing health awareness and digital healthcare adoption, women are taking charge of their well-being like never before. Early diagnosis and timely intervention are crucial in addressing reproductive health challenges, and digital health solutions are playing a vital role in bridging the gap between patients and specialists. #WomensHealth #Gynecology #ReproductiveHealth #PCOS #FertilityCare #HealthcareTrends #DigitalHealth #WomenWellness #Dseidehealthcarenetwork Source: ET HealthWorld.com

At least 30 startups secured more than $355 million this week, which included three growth-stage and 20 early-stage deals. This is stupendous growth of at least 355 per cent from the previous week, when the domestic startup ecosystem witnessed $105.87 million in fund-raising by 21 startups. HR tech platform DarwinBox topped the chart with $140 million in Series D round led by Partners Group and KKR. The round also saw participation from Gravity Holdings. Edtech platform Leap Finance secured $100 million debt facility from London headquartered-HSBC Bank under its ASEAN Growth Fund. This follows Leap’s $65 million Series E equity round led by Apis Partners last month, taking it total fundraise to over $400 million. Insurtech startup InsuranceDekho secured $70 million, which was co-led by private equity fund Beams Fintech Fund, Japan’s Mitsubishi UFJ Financial Group (MUFG) and insurer BNP Paribas Cardif, via its insurtech fund managed by European investment major Eurazeo. Meanwhile, 20 early-stage startups secured funding worth $45.02 million, led by revenue AI platform MaxIQ and enterprise tech startup Beacon.li, among others. Bengaluru-based startups led with 12 deals followed by Delhi-NCR, Mumbai and others. Domestic startups raised a total of nearly Rs 13,800 crore ($1.65 billion) in February this year, a 19.5 per cent increase from nearly Rs 11,460 crore ($1.38 billion) in January. The median valuation of these startups in February 2025 stood at Rs 61,216 crore ($83.2 billion). Over the course of the 2024-25 financial year, Indian startups collectively raised Rs 21,062 crore ($25.4 billion) across 2,200 funding rounds. Meanwhile, the Indian tech startup ecosystem now ranks second, after the US, in terms of all-time funding raised by companies with women founders, with a total of $26 billion in this space to date. India is home to over 7,000 active women-led startups, accounting for 7.5 per cent of all active startups in the country. Source: thestatesman #healthcarestartup #funding #startupindia #dseidehealthcarenetwork

In 2025, healthtech startups are revolutionizing healthcare by integrating advanced technologies to enhance patient outcomes and streamline medical processes. Here are five leading innovators making significant strides: 1. Tricog Health: Leveraging artificial intelligence, Tricog Health offers real-time ECG analysis, enabling rapid and accurate cardiac diagnostics. Their cloud-based platform facilitates early detection of heart conditions, improving patient survival rates. 2. Qure.ai: Specializing in AI-driven radiology solutions, Qure.ai automates the interpretation of medical images, expediting diagnosis and treatment plans. Their technology has been pivotal in detecting conditions like tuberculosis and COVID-19, especially in regions with limited access to radiologists. 3. BioBeat: BioBeat's wearable devices provide continuous monitoring of vital signs such as heart rate, blood pressure, and oxygen saturation. Utilizing AI, their platform alerts healthcare providers to potential health issues in real-time, facilitating proactive patient management. 4. Lucira Health: Pioneering rapid at-home diagnostics, Lucira Health offers single-use test kits for infectious diseases like COVID-19 and influenza. Their FDA-approved molecular tests deliver lab-quality results within minutes, empowering individuals with timely health information. 5. 52 North Health: Focused on personalized medicine, 52 North Health utilizes AI and data analytics to create tailored treatment plans for chronic diseases such as cancer and diabetes. Their approach enhances patient outcomes by considering individual genetic and lifestyle factors. These startups exemplify the transformative potential of technology in healthcare, making medical services more accessible, efficient, and personalized. #Healthtech #AIinHealthcare #DigitalHealth #MedTechInnovations #HealthcareStartups #Dseidehealthcarenetwork Source: CIOL

In the short term, TakeMe2Space’s go-to-market strategy will prioritize the adoption of satellite subsystems developed by the company across India, Australia, and Europe. The startup has already made significant strides in its space missions, having completed two successful missions in collaboration with ISRO’s POEM (Payloads and Orbital Experiments Module) platform TakeMe2Space, a SpaceTech startup, has successfully raised Rs 5.5 crore in a pre-seed funding round led by Seafund. The round also saw participation from Blume Ventures, Artha Venture Fund, AC Ventures, and several prominent angel investors. Founded in 2024 by Ronak Kumar Samantray, TakeMe2Space aims to address data processing challenges in space through innovative satellite applications. The company plans to use the funds raised to develop and launch MOI-1, India’s first AI laboratory in space, which will provide satellite research opportunities for early customers. The startup has already made significant strides in its space missions, having completed two successful missions in collaboration with ISRO’s POEM (Payloads and Orbital Experiments Module) platform. During these missions, TakeMe2Space demonstrated a novel radiation shielding coat. TakeMe2Space’s focus is on enhancing domestic capabilities in areas such as radiation shielding, propulsion systems, and inter-satellite communications. The company plans to further develop these technologies to empower the space sector and provide accessible space research opportunities. In the short term, TakeMe2Space’s go-to-market strategy will prioritize the adoption of satellite subsystems developed by the company across India, Australia, and Europe. These efforts will focus on ensuring a smooth experience for over 15 early customers running orbital applications on the MOI-1 AI lab. The company has expanded rapidly in the past year, growing its team to over 17 members. The engineering staff has been involved in the development of more than 15 satellite sensors and subsystems. TakeMe2Space’s key achievements include the MOI-TD mission, which demonstrated the ability to uplink large AI models from a ground station, execute external code on the satellite, and securely downlink encrypted results. Additionally, the mission successfully validated critical subsystems such as sensors (Sun Sensor, Horizon Sensor, Solar Cell, IMUs), actuators (MagnetoTorquers, AirTorquers, Reaction Wheel), and computing infrastructure (Zero Cube AI Accelerator, POEM Adapter Board). Source: Financial Express #healthcarestartupfundingindia #startupfunding #dseidehealthcarenetwork

India’s health tech startups have been battling a prolonged funding winter, with investors exercising caution amid global economic uncertainties. However, the government’s ₹10,000 crore Fund of Funds for Startups (FFS) could be a game-changer, offering much-needed financial support to early-stage and growth-stage ventures. Managed by SIDBI, the FFS aims to infuse capital into startups through Alternative Investment Funds (AIFs). While the corpus is sector-agnostic, health tech startups could benefit significantly, given their critical role in India’s healthcare transformation. With the increasing adoption of AI-driven diagnostics, telemedicine, and digital health solutions, access to capital is crucial for scaling innovation. However, challenges remain. Bureaucratic hurdles, lengthy approval processes, and limited direct funding could slow down impact realization. Additionally, many health tech startups require sector-specific funds catering to regulatory complexities and long product development cycles. To maximize benefits, a targeted health tech fund under the FFS umbrella could be a strategic move, ensuring that India’s rapidly evolving med-tech landscape doesn’t lose momentum. The initiative signals positive intent, but sustained investor confidence and policy support will determine its real impact. #HealthTech #StartupFunding #DigitalHealth #MedTech #IndianStartups #FundingWinter #Dseidehealthcarenetwork Source: IndiaMed Today

Indian startups raised a total of nearly Rs 13,800 crore ($1.65 billion) in February this year, a 19.5 per cent increase from nearly Rs 11,460 crore ($1.38 billion) in January, according to a new report. The median valuation of these startups in February 2025 stood at Rs 61,216 crore ($83.2 billion). Over the course of the 2024-25 financial year, Indian startups collectively raised Rs 21,062 crore ($25.4 billion) across 2,200 funding rounds. Bengaluru, known as India's startup hub, secured the highest funding in February 2025, raising $353 million, according to data by Traxcn. The median round size in Bengaluru was $2 million. Mumbai entrepreneurs also saw significant funding, with $102 million raised, but with a higher median round size of $5 million. In terms of AI startup investments, India has seen a steady rise in funding over the years. The total funding for AI startups in India during 2024 reached $164.9 million, over 50 per cent up from $108.3 million in 2023. From 2019 to 2025, AI-focused startups in India have continued to secure crucial investments, showcasing India's increasing importance in the global AI ecosystem, according to Traxcn data. With more than 1.59 lakh startups recognised by the Department for Promotion of Industry and Internal Trade (DPIIT), India has firmly established itself as the third-largest startup ecosystem in the world. About 21 Indian startups collectively raised approximately $105.87 million last week, with securing funding across different stages. Among them, three startups raised funds at the growth stage, while 16 early-stage startups attracted investments. In the previous week, nearly 22 startups raised around $184.4 million. On average, in the last eight weeks, startup funding has stood at approximately $317.35 million per week, with around 28 deals taking place weekly. Source: The Hans India #healthcarestartupfundingindia #AIinhealthcare #dseidehealthcarenetwork

The future of healthcare is being shaped by groundbreaking medical device startups. Companies like Eko Health (AI-powered stethoscopes) and Neurescue (AI-guided cardiac arrest solutions) are enhancing diagnostics and emergency care. Cala Health is tackling neurological disorders with wearable bioelectronic therapies, while Synchron is developing brain-computer interfaces for patients with paralysis. Tivic Health focuses on bioelectronic medicine for sinus relief. Startups like Butterfly Network (portable ultrasound) and Exo (AI-driven imaging) are making advanced diagnostics more accessible. Nutromics is innovating real-time biomarker monitoring, and Xsensio is bringing wearable sensing technology to the next level. Endiatx is redefining endoscopy with pill-sized robots, while BiVACOR is working on the world’s first total artificial heart. These companies are set to transform patient care, making healthcare smarter, faster, and more effective. #MedTech #HealthcareInnovation #MedicalDevices #DigitalHealth #FutureOfHealthcare #AIinHealthcare #Dseidehealthcarenetwork Source: Global Corporate Venturing

Arva Health, a cutting-edge fertility care startup, has raised $1 million in a pre-seed funding round to enhance accessibility and innovation in reproductive healthcare. The investment will fuel the development of AI-driven fertility solutions, personalized treatment plans, and advanced diagnostics, empowering individuals and couples on their parenthood journey. With a mission to bridge gaps in fertility care, Arva Health aims to integrate digital health solutions with expert medical guidance, ensuring a seamless experience for patients. The funding round saw participation from prominent angel investors and venture capital firms, underscoring the growing demand for tech-driven fertility solutions. This milestone marks a significant step toward transforming reproductive health through technology, making fertility treatments more efficient, affordable, and patient-centric. #ArvaHealth #FertilityTech #HealthcareInnovation #StartupFunding #DigitalHealth #ReproductiveHealth #AIinHealthcare #Dseidehealthcarenetwork Source: Outlook Business

The Department for Promotion of Industry and Internal Trade (DPIIT) has introduced the Startup Maha Rathi challenge as part of the second edition of Startup Mahakumbh, aiming to provide startups across India with Rs 30 crore in funding, mentorship from industry experts, and networking opportunities with global investors. The initiative also includes special awards for innovative startups. Covering 11 key sectors such as AI & DeepTech, biotechnology & healthcare, gaming & sports, fintech, mobility, agritech, precision manufacturing, D2C, climate tech, and Defence & SpaceTech, the competition will conclude with a live pitching finale from April 3-5, 2025, at Bharat Mandapam, New Delhi. Union Commerce and Industry Minister Piyush Goyal will present the awards. The multi-phase selection process began with applications opening on February 26, 2025. Shortlisted startups for the grand jury round will receive Rs 1 lakh, while the top two from each sector will be awarded Rs 10 lakh each. The next five will secure Rs 5 lakh, and an additional five will get Rs 3 lakh each. Beyond financial support, participants will gain expert guidance and investor access from a jury comprising 100+ VCs, angel investors, and industry specialists. The Startup Maha Rathi challenge is backed by Avaana Capital, LetsVenture, Karnataka Digital Economy Mission (KDEM), IVCA, and HDFC, reinforcing its commitment to fostering India's entrepreneurial ecosystem. Startup Mahakumbh, a premier event uniting startups, investors, incubators, accelerators, and industry leaders, is making a grand return in 2025 after a successful inaugural edition. The previous edition attracted over 48,581 business visitors, 1,306 exhibitors, and leading names from 26 states and 14 countries, establishing itself as a key platform for India's startup growth. Source: bwdisrupt #healthcarestartupfundingindia #funding #maharathichallenge #dseidehealthcarenetwork

Srinagar, Feb 28: The Department for Promotion of Industry and Internal Trade (DPIIT), in collaboration with Avaana Capital, LetsVenture, Karnataka Digital Economy Mission (KDEM), IVCA, HDFC, and others, has announced the launch of the Startup Maha Rathi challenge as part of the second edition of Startup Mahakumbh. A statement said that this flagship initiative aims to empower Indian startups nationwide with funding, mentorship, and strategic guidance, aligning with India’s long-term vision of becoming a developed economy (Viksit Bharat) by 2047. The challenge will provide access to a fund pool of up to Rs 30 crore, mentorship from industry experts, and networking opportunities with global investors. Additionally, special awards will be given to innovative startups from emerging states and union territories through a dedicated program. “Startup Maha Rathi – Rising towards Viksit Bharat” is designed for entrepreneurs across 11 key sectors: AI & DeepTech, BioTech & Healthtech, Gaming & Sports, Fintech, Incubators & Accelerators, Mobility, Agritech, B2B & Precision Manufacturing, D2C, ClimateTech, and Defence & SpaceTech. Awards will be presented in the presence of the Honorable Minister of Commerce and Industry. Selected startups will gain exposure to global markets through Startup India, access to mentorship from industry veterans, investor networking opportunities, and national-level recognition by DPIIT. The competition follows a structured, multi-phase selection process, beginning with applications launching on February 26, 2025, and culminating in a live pitching finale from April 3-5, 2025, at Bharat Mandapam, New Delhi. Each startup shortlisted for the grand jury round will receive a guaranteed Rs 1 lakh. The top two startups from each sector will be awarded Rs 10 lakh each, while the next five will receive Rs 5 lakh each. The following five startups in each track will receive Rs 3 lakh each. Beyond financial grants, participating startups will receive expert guidance and investor access through a jury comprising over 100 leading VCs, angel investors, and domain specialists from Startup India and organizations including Avaana Capital, LetsVenture, KDEM, IVCA, and HDFC. Piyush Goyal, Union Minister for Commerce and Industry, said, “The Startup Maha Rathi initiative marks a pivotal stride toward achieving India’s vision of ‘Viksit Bharat 2047.’ By offering strategic financial support and expert mentorship, this initiative will empower the nation’s most promising startups to scale, innovate, and drive transformative change, strengthening India’s position as a global leader in entrepreneurship and innovation.” Amardeep Singh Bhatia, Secretary, DPIIT, added, “India’s startup ecosystem is at an inflection point, and initiatives like this are crucial in ensuring that high-potential ventures receive the right support to thrive. By enabling a strong innovation-driven culture, the initiative will play a pivotal role in shaping the next generation of disruptive entrepreneurs.” Applications for Startup Maha Rathi 2025 will open on February 26, 2025, with a deadline of March 7, 2025. Shortlisted startups will present virtually to a jury panel between March 15-25. Eligible startups must be DPIIT-recognized entities in their early or growth stages, operating in India as a Private Limited Company, LLP, or Partnership Firm. Source: Greater Kashmir #healthcarestartupfunding #funding #dseidehealthcarenetwork

The Government Institute of Medical Sciences (GIMS) has announced a ₹2.5 crore grant to support innovative research startups in the healthcare sector. This initiative aims to empower early-stage med-tech, biotech, and digital health ventures by providing them with the necessary funding and infrastructure to accelerate their breakthroughs. With a strong focus on cutting-edge medical research, AI in healthcare, and advanced diagnostics, GIMS is fostering a thriving ecosystem for startups to develop game-changing solutions. Entrepreneurs and researchers can now leverage this opportunity to bring impactful innovations to life and contribute to the future of healthcare. Stay ahead in the health-tech revolution—apply now and be part of this transformative journey! #GIMS #HealthcareInnovation #MedTech #HealthTechStartups #AIinHealthcare #Biotech #ResearchFunding #StartupGrants #MedicalBreakthroughs #DigitalHealth #Dseidehealthcarenetwork Source: The Times Of India

Earthful, a Shark Tank India-featured nutrition brand, has raised ₹5 crore in its latest funding round, marking a significant milestone in its mission to redefine health and wellness. Known for its science-backed, plant-based nutrition solutions, Earthful has quickly gained traction among health-conscious consumers seeking natural, clean, and effective supplements. The fresh capital will be utilized to scale production, expand product offerings, strengthen distribution channels, and enhance brand presence across India. With a strong focus on innovation and sustainability, Earthful is set to disrupt the Indian nutrition market by providing high-quality, research-driven products tailored for modern lifestyles. Founded with the vision of making nutrition accessible and transparent, Earthful has been a game-changer in the health tech space, offering a range of superfoods, protein blends, and wellness supplements free from artificial additives. The brand’s commitment to quality and efficacy has won over investors and customers alike. With this funding boost, Earthful aims to further its reach and impact, empowering individuals to lead healthier lives through informed nutrition choices. #Earthful #SharkTankIndia #FundingNews #NutritionRevolution #HealthTech #Wellness #PlantBased #StartupSuccess #HealthyLiving #Dseidehealthcarenetwork Source: Indian Startup News

Quick Clean, a leading professional linen management solutions provider, has successfully raised Rs 50 crore ($5.7 million) in its Series A funding round. The investment was led by Alkemi Growth Capital and Blue Ashva Capital, with an additional Rs 10 crore ($1.15 million) debt investment from Venture Debt Cos., the company announced. Quick Clean plans to utilise the fresh capital to expand its footprint in the healthcare and hospitality sectors, reinforcing its leadership in India’s $36 billion commercial laundry industry. The company emphasises innovation-driven hygiene solutions, leveraging advanced chemistry and cutting-edge technology. “When it comes to a customer or patient, there’s no room for compromise. Linen quality and hygiene must unnegotiably be ensured through researched processes, novel chemistry, and cutting-edge technology, not age-old human practices,” said CA Anshul Gupta, Founder and CEO of Quick Clean. Alka Goel, Founder of Alkemi Growth Capital, highlighted the critical need for advanced, hygienic laundry solutions in the healthcare sector, especially in reducing hospital-acquired infections. “With rising healthcare demands and an increasing emphasis on safety protocols, our focus on this sector is driven by the urgent need for solutions that enhance infection prevention,” she noted. Since its founding in 2010 by brothers Anshul and Ankur Gupta, Quick Clean has grown into a major player in the industry. The company operates in 36 cities across India, with over 3,000 installed machines servicing more than 120 five-star hotels and healthcare institutions, including Taj, Marriott, Fairmont, ITC, Radisson, AIIMS, and PMCH. To date, Quick Clean has processed over 600 million kg of linen, saved 210 million litres of water, and reduced carbon emissions by 60 million kilograms. Recognised for its sustainability efforts, Quick Clean is the first registered energy-saving corporation in the laundry industry with the Bureau of Energy Efficiency. The company has also received two prestigious global awards from CINET Global: the Best Practice Award for Sustainability and the Overall Best Practice Award in the Commercial Laundry segment in 2020. Source: Startup Story Media #healthcarestartupfunding #funding #dseidehealthcarenetwork

Jobizo, an AI-driven healthcare HRtech platform, has successfully raised $1.4 million in a pre-Series A funding round led by Alkemi Growth Capital. This investment follows a $500,000 seed funding round led by AROA Ventures in 2022, which propelled the company's growth by over 500%. Co-founded by Naveen Trehan and Avishek Agarwal, Jobizo connects employers with skilled healthcare professionals. The platform has facilitated over 20,000 jobs both in India and internationally, contributing to more than 10 million additional patient care hours. With the new funding, Jobizo aims to create 100,000 healthcare jobs in India and 3,000 jobs abroad within the next 18 months, targeting the completion of 10 million job hours over time. Leveraging its expanding investor network and market expertise, the company seeks to address skill gaps and foster a supportive environment for the healthcare workforce. This strategic investment underscores the growing confidence in technology-driven solutions to meet the evolving demands of the healthcare sector. Source: Medical Dialogues #Jobizo #HealthcareRecruitment #HRTech #FundingNews #StartupFunding #PreSeriesA #HealthcareJobs #AIinHealthcare #JobPlacement #HealthcareInnovation #MedTech #InvestorNews #AlkemiGrowthCapital #TechForGood #dseidehealthcarenetwork

India is making a bold move to solidify its position as a global pharmaceutical powerhouse with a ₹5,000 crore revitalization plan. This initiative focuses on boosting domestic manufacturing, fostering innovation, and reducing dependency on imports. By enhancing R&D capabilities and streamlining regulatory processes, India aims to strengthen its leadership in generics, biosimilars, and high-value drug production. A key component of this plan is the expansion of pharmaceutical clusters and the promotion of bulk drug parks, ensuring self-reliance in active pharmaceutical ingredients (APIs). Additionally, the government is encouraging partnerships between industry and academia to drive breakthroughs in biotechnology and precision medicine. With the global pharma market projected to exceed $1.5 trillion, India is positioning itself as a key supplier of affordable and high-quality medicines. This initiative will not only boost exports but also create thousands of jobs, strengthening the country’s healthcare ecosystem. By investing in innovation and infrastructure, India is set to redefine its role in global healthcare. #IndiaPharma #PharmaDominance #HealthcareInnovation #MakeInIndia #BiotechRevolution #PharmaExports #APIManufacturing #DrugDiscovery #MedTech #GlobalHealthcare #Dseidehealthcarenetwork

India’s software-as-a-service (SaaS) sector experiences a significant investment surge in 2025. Artificial intelligence (AI) is the primary driver. Funding sources shift towards AI-powered SaaS solutions. This change reflects investor confidence in the sector’s future. Data from industry analysis firms indicate a 30% increase in venture capital funding for Indian SaaS companies in the first half of 2025. A large portion of this capital targets firms that integrate AI into their products. This trend marks a shift from previous years. Earlier investments focused on general SaaS platforms. Now, investors prioritize AI capabilities. Companies focused on AI-driven analytics, automation, and customer service receive the most attention. Startups that offer AI-powered solutions for specific industries, such as healthcare and finance, gain traction. For example, a Bengaluru-based startup, “DataLens AI,” secured $15 million in Series A funding. DataLens AI provides AI-driven data analytics for the retail sector. Their platform helps retailers predict customer behavior and optimize inventory. The Indian government’s support for AI also plays a role. National AI initiatives and policies promote AI development. This creates a favorable environment for AI-focused SaaS companies. The government’s “AI for All” program encourages AI adoption across various sectors. This program provides funding and resources for AI research and development. Investors cite the growing demand for AI-powered solutions as a key factor. Businesses seek tools to improve operations and reduce costs. AI helps companies automate tasks and gain insights from data. This need drives the demand for AI-based SaaS products. Market analysts report that the Indian SaaS market is set to expand rapidly. The growth of digital infrastructure and the increasing adoption of cloud computing support this expansion. Companies of all sizes move to cloud-based solutions. This transition creates opportunities for SaaS providers. A report published by “Tech Insights India” shows that the SaaS market will reach $50 billion by 2030. This growth is attributed to the increasing demand for cloud-based applications and the rise of AI. The report indicates that AI-powered SaaS solutions will constitute a significant portion of this market. Industry experts point to the competitive advantage of Indian SaaS companies. These companies offer cost-effective solutions. Many Indian SaaS firms develop products with global markets in mind. This strategy helps them attract international customers. The rise of remote work also contributes to the increased demand for SaaS tools. Companies need tools to manage remote teams and workflows. SaaS solutions provide the necessary tools for collaboration and communication. AI further enhances these tools by automating tasks and providing insights. Challenges remain for the Indian SaaS sector. Access to skilled talent is a major concern. The demand for AI engineers and data scientists exceeds the supply. Companies invest in training programs to address this gap. Regulatory hurdles also present challenges. Companies must navigate complex data privacy and security regulations. Despite the challenges, the Indian SaaS sector shows strong growth potential. AI provides a new wave of opportunities. Investors are optimistic about the sector’s future. The focus on AI-powered solutions is expected to continue. The sector will see increased competition and further investment. Source: pc-tablet #healthcarestartup #startupcompaniesindia #dseidehealthcarenetwork

Global investment firm KKR has acquired a controlling stake in Healthcare Global Enterprises (HCG) for $400 million, further expanding its footprint in India's healthcare sector. HCG, a leading provider of cancer care, operates a network of comprehensive oncology centers, multispecialty hospitals, and fertility clinics across India. With this strategic acquisition, KKR aims to enhance cancer care services, drive innovation, and expand HCG’s network to meet the growing demand for specialized oncology treatments. The investment underscores the increasing interest of global private equity players in India's fast-growing healthcare industry, driven by rising healthcare needs and technological advancements. HCG’s expertise in precision oncology, advanced diagnostics, and cutting-edge treatment protocols makes it a valuable addition to KKR’s healthcare portfolio. The partnership is expected to accelerate technological adoption, patient-centric care, and infrastructure development, reinforcing HCG’s position as a leader in oncology care in India. This acquisition aligns with KKR’s long-term vision of supporting high-quality healthcare providers and fostering innovation in critical care services. The deal marks a significant milestone in India's healthcare investment landscape, promising better access to world-class cancer treatment. #KKR #HealthcareInvestment #HCG #OncologyCare #PrivateEquity #HealthcareInnovation #CancerTreatment #HealthTech #MedicalAdvancements #Dseidehealthcarenetwork Source: Bio Spectrum

Deadline Extended for Investor connect session at GAFX 2025! IT BT Department, Karnataka is hosting the Investor Connect Session at Bengaluru GAFX 2025, offering Karnataka's innovative AVGC-XR startups a golden opportunity to pitch directly to leading angel investors and VCs. Our mission is to transform Karnataka into a global AVGC hub, and through this initiative, we're connecting visionary startups with investors who understand the immense potential of our state’s ecosystem. We're looking for pioneering startups in AVGC-XR, AI in AVGC, and related domains to join this exclusive closed-room pitching session. Here is your opportunity to secure funding, mentorship and strategic partnerships! Register now: https://lnkd.in/g7D2scE8 (Last date: 23rd FEB, 5PM) For queries: +91 9493478660

In a significant policy shift, President Donald Trump has signed an executive order initiating the United States' withdrawal from the World Health Organization (WHO) for the second time in less than five years. This decision, announced on January 20, 2025, has profound implications for global health initiatives and India's healthcare industry. Global Health Implications The U.S. has been a major contributor to the WHO, providing nearly $1.3 billion over two years until 2023, accounting for about 15% of the organization's total funding. The withdrawal entails a 12-month notice period during which the U.S. will cease funding and reassign federal personnel involved with the WHO. This move raises concerns about the WHO's capacity to manage international health crises, including pandemics and diseases like AIDS, malaria, and tuberculosis. Experts warn that the absence of U.S. support could undermine vital health programs, disrupt international collaborations, and hinder responses to global health emergencies. The WHO has expressed regret over the U.S. decision, emphasizing the longstanding partnership that has led to significant health milestones worldwide. The organization highlighted its crucial role in combating diseases such as Ebola and polio, particularly in underprivileged regions. Implications for India's Healthcare Industry India, as a significant player in global healthcare, could experience both direct and indirect effects from the U.S. withdrawal. The WHO collaborates closely with Indian health authorities on various programs, including immunization drives, disease eradication efforts, and health system strengthening. Reduced funding and support may lead to scaling back of these initiatives, potentially impacting public health outcomes. Moreover, India's pharmaceutical industry, known for its substantial generic drug production, benefits from WHO prequalification programs that facilitate global distribution. Changes in WHO operations could affect the approval and export processes, influencing market dynamics and access to affordable medications worldwide. Additionally, the U.S. withdrawal may alter global health governance structures, prompting India to reassess its role and contributions within the international health community. This situation presents an opportunity for India to take on a more prominent leadership position in advocating for and supporting global health initiatives. In summary, the U.S. exit from the WHO introduces uncertainties in global health efforts and poses challenges for India's healthcare industry. It underscores the need for sustained international collaboration and support to address health challenges effectively. Source: eHealth #USWHOWithdrawal #GlobalHealthCrisis #WHO #HealthcarePolicy #PublicHealth #IndiaHealthcare #HealthDiplomacy #TrumpPolicy #MedicalImpact #HealthSecurity #PandemicPreparedness #PharmaIndustry #GlobalHealth #dseidehealthcarenetwork

Between February 17 and February 22, 2025, Indian startups collectively raised over $177 million across 16 funding rounds, showcasing the country's dynamic entrepreneurial landscape. Leading the pack, B2B e-commerce platform Udaan secured $75 million in its Series G funding round, underscoring its significant role in streamlining business-to-business transactions. ENTRACKR.COM In the wealth management sector, Waterfield Advisory attracted $18 million in a round led by Jungle Ventures, aiming to enhance its advisory services. SaaS company Spyne raised $16 million to advance its AI-driven solutions for businesses. ENTRACKR.COM The early-stage funding scene was equally vibrant, with 12 startups amassing a total of $33.4 million. Notably, enterprise AI startup Singulr AI led this segment by securing $10 million in seed funding, reflecting growing investor confidence in artificial intelligence ventures. ENTRACKR.COM Bengaluru emerged as the frontrunner, hosting 12 of the total deals, highlighting its status as India's startup hub. Sector-wise, AI startups dominated with five deals, followed by foodtech with three, indicating robust growth in these industries. ENTRACKR.COM This funding surge underscores the resilience and diversity of India's startup ecosystem, attracting substantial investments across various sectors and stages. #IndianStartups #FundingNews #Udaan #Spyne #SingulrAI #BengaluruStartups #AIFunding #StartupEcosystem #dseidehealthcarenetwork Source: Indian Startup News

IT BT Department, Karnataka extends its warm congratulations to Google on the inauguration of 'Ananta', their state-of-the-art Global Capability Center in Bengaluru. This landmark facility, designed to host 5,000 technology professionals, exemplifies Bengaluru's position as India's preferred destination for Global Capability Centers. We commend Google's thoughtful approach to sustainable development, incorporating advanced environmental features and locally sourced materials. The establishment of this center aligns perfectly with our vision of strengthening Karnataka's technology leadership. We are confident that Ananta will drive significant innovations in artificial intelligence and digital technologies, benefiting both India and global markets. We look forward to supporting Google's growth journey in Karnataka.

The Karnataka State Cabinet has approved funding allocations of over ₹350+ Crores for technology and innovation development across the state. ₹75 Crores has been allocated for Seed Funds to support startups in Tier II and III cities including Mysuru, Mangaluru, and Hubballi, extending the Startup/Innovation ecosystem beyond Bengaluru. The approval of SFAL 2.0 (Semiconductor Future Accelerator Lab) will advance semiconductor design IP creation, support fabless startups and electronics MSMEs, and develop specialized workforce skills, positioning it to become India's premier semiconductor design accelerator. The Cabinet has also sanctioned ₹285 Crores for International Institute of Information Technology Bangalore IIIT-B development as part of a ₹817 Crore development project, with the remaining ₹532 Crores to be funded through CSR and the institute's resources. These initiatives aim to strengthen Karnataka's technology infrastructure and promote balanced regional growth beyond Bengaluru!

Acute Myeloid Leukemia (AML) is a rapidly progressing blood cancer that requires urgent and specialized treatment. In India, access to timely diagnosis and advanced therapies remains a challenge due to high treatment costs, lack of awareness, limited bone marrow transplant facilities, and late-stage diagnosis. Many patients face delays due to financial constraints, inadequate insurance coverage, and insufficient access to specialized oncology centers, especially in rural areas. Despite these challenges, innovative solutions are emerging. Expanding government initiatives like Ayushman Bharat, strengthening public-private partnerships, and increasing funding for cancer research can enhance accessibility. Digital health solutions, including AI-driven diagnostics and telemedicine, are bridging the gap for remote patients. More awareness campaigns and early screening programs are also essential to improve survival rates. India needs a multi-pronged approach to combat AML—better affordability, improved healthcare infrastructure, and advancements in precision medicine. Strengthening bone marrow donor registries and fostering global collaborations can further aid treatment outcomes. With the right interventions, India can transform AML care and offer hope to thousands of patients. Source: THE HINDU #AcuteMyeloidLeukemia #AMLIndia #CancerCare #Oncology #HealthcareInnovation #LeukemiaAwareness #DigitalHealth #BoneMarrowTransplant #AffordableHealthcare #MedicalResearch #dseidehealthcarenetwork

Apollo Hospitals is championing the ‘Heal in India’ initiative, positioning India as a premier destination for medical tourism. With world-class infrastructure, cutting-edge technology, and highly skilled healthcare professionals, Apollo aims to attract international patients seeking high-quality, cost-effective treatments. The group is expanding its international patient care services, offering seamless experiences from consultation to recovery. With a focus on specialized treatments like organ transplants, robotic surgeries, and advanced cancer care, Apollo is set to enhance India’s reputation as a global healthcare leader. To support this mission, Apollo is leveraging AI-driven healthcare solutions, telemedicine, and multilingual support systems to ensure ease of access for patients worldwide. Additionally, collaborations with government bodies and medical facilitators are strengthening India’s position in the global healthcare ecosystem. As healthcare demand rises, Apollo’s commitment to innovation, patient-centric care, and digital health solutions will play a key role in driving medical tourism. The ‘Heal in India’ initiative is not just about treatment—it’s about transforming India into the healthcare capital of the world. #HealInIndia #MedicalTourism #ApolloHospitals #HealthcareInnovation #MedTech #GlobalHealth #DigitalHealth #AffordableHealthcare #IndiaHealthcare #AIinHealthcare #Dseidehealthcarenetwork

The Whole Truth (TWT), a Mumbai-based clean-label health food brand, has successfully raised $15 million in a Series C funding round led by Belgian investment firm Sofina. This round also saw continued support from existing investors, including Z47 (formerly Matrix Partners India), Peak XV Partners, and Sauce.VC. Notable angel investors such as Nithin Kamath of Zerodha, Sriharsha Majety of Swiggy, and Jaydeep Barman of Rebel Foods have previously backed the company. Founded in 2019 by ex-Unilever marketer Shashank Mehta, TWT was born out of Mehta's personal journey to combat obesity and his realization of the misleading claims prevalent in the packaged food industry. The brand is committed to offering products free from hidden sugars and harmful additives, aiming to restore transparency and trust in the food sector. Its diverse product lineup includes protein bars, peanut butter, dark chocolates, energy bars, immunity balls, muesli, and recently introduced 100% clean, super-light protein powders. These offerings cater to a broad audience, extending beyond traditional fitness enthusiasts to include women, teenagers, and older adults. The newly acquired funds are earmarked for expanding TWT's in-house manufacturing capabilities, talent acquisition, and driving growth across various product categories. This strategic investment aligns with TWT's mission to challenge long-standing norms in India's $40 billion packaged food industry. The company has experienced significant growth, with revenues increasing to ₹65.3 crore in FY24 from ₹35.96 crore in FY23, marking an 81% year-on-year surge. Simultaneously, TWT has managed to reduce its losses by 33% during the same period. Vikram Vaidyanathan, Managing Director at Z47, expressed confidence in TWT's trajectory, stating, "Shashank and the team at The Whole Truth are not just building a brand—they're leading a movement to restore trust in food; and making food real again." Yana Kachurina, Principal at Sofina, echoed this sentiment, highlighting the alignment of TWT's mission with Sofina's vision to build a healthier food ecosystem. Operating primarily through its website, TWT claims that 80-85% of its sales are direct-to-consumer, with the remainder generated through partnerships. The brand competes with other health-focused companies such as Yoga Bar, Slurrp Farm, True Elements, Open Secret, and Monsoon Harvest. With the fresh infusion of capital, TWT is poised to further its mission of redefining clean-label nutrition and expanding its footprint in the health food market. Source : StartupNews #TheWholeTruth #HealthFood #CleanLabel #FundingNews #StartupFunding #FoodTech #HealthyEating #Nutrition #Sofina #Investment #SeriesCFunding #DTCBrand #ProteinBars #HealthySnacking #FoodInnovation #IndianStartups #ConsumerBrands #Wellness #TransparencyInFood #dseidehealthcarenetwork

United States President Donald Trump has said that he will impose tariffs on automobile, semiconductor and pharmaceutical imports of around 25 percent and the announcement is set to come as soon as April 2. The new duties, if implemented, would widen the president’s trade war. Earlier, the US President has announced 25 per cent tariffs on steel and aluminum that are set to take effect in March. On Tuesday, he shared specifics details on which other sectors would be hit with fresh barriers. “I probably will tell you that on April 2, but it’ll be in the neighbourhood of 25 per cent,” Trump told reporters at his Mar-a-Lago club when asked about his plan for auto tariffs. Asked about similar levies on pharmaceutical drugs and semiconductor chips, the president said: “It’ll be 25 per cent and higher, and it’ll go very substantially higher over a course of a year.” Trump said he wanted to give companies “time to come in” before announcing new import taxes. “When they come into the United States and they have their plant or factory here there is no tariff, so we want to give them a little bit of a chance,” he said, as quoted by Financial Post. According to Financial Post report, many economists say they would raise consumer prices for Americans and hinder the fight against inflation. Trump also announced that he would apply “reciprocal” levies on a country-by-country basis as soon as April. However, specific details are yet to be determined. He has also threatened duties on some of the U.S.’s biggest trading partners, such as a 10 per cent rate already applied to China and 25 per cent tariffs on Canada and Mexico that have been deferred until at least March 4. Source: Financial Express #healthtechstartupinindia #healthtech #dseidehealthcarenetwork

The Indian Institute of Technology Guwahati (IIT-G) has signed a Memorandum of Understanding (MoU) to promote its cutting-edge C-Phycocyanin (C-PC) production technology, aiming to revolutionize the health and pharmaceutical industries. C-Phycocyanin, a natural blue pigment derived from Spirulina, is known for its potent antioxidant, anti-inflammatory, and neuroprotective properties, making it highly valuable for pharmaceutical, nutraceutical, and cosmetic applications. The collaboration focuses on scaling up the production of high-purity C-PC using IIT-G’s advanced biotechnological innovations. This sustainable, cost-effective production method enhances the commercial viability of C-PC, paving the way for its widespread use in therapeutic formulations, immune-boosting supplements, and anti-cancer treatments. Researchers at IIT-G highlight the growing global demand for natural, plant-based bioactive compounds, positioning C-PC as a promising alternative to synthetic dyes and pharmaceutical additives. The MoU aims to facilitate industry partnerships, enabling mass production and commercialization of this high-value biomolecule. Through this initiative, IIT-G reinforces its commitment to bridging scientific research with industry applications, fostering innovation in biopharma and healthcare. The technology’s adoption is expected to drive advancements in drug development, functional foods, and wellness products, contributing to a more sustainable and health-conscious future. Source: Bio Spectrum

NeuraSim, a leader in AI-driven healthcare simulations, has partnered with QWR to introduce an innovative AI-powered immersive VR therapy designed to transform mental health treatment. This cutting-edge solution leverages advanced artificial intelligence and virtual reality to create personalized, interactive therapy sessions tailored to individual patient needs. The AI-powered VR therapy provides a fully immersive experience, allowing patients to engage in real-time therapeutic simulations guided by AI-driven behavioral analysis. By adapting dynamically to a user’s emotional responses, the system enhances cognitive behavioral therapy (CBT), exposure therapy, and mindfulness training with high precision. Clinicians can customize therapy programs based on patient progress, making mental health treatment more engaging, accessible, and effective. The solution is particularly beneficial for individuals dealing with anxiety, PTSD, and stress-related disorders, offering a safe and controlled environment for gradual exposure and emotional regulation. With this collaboration, NeuraSim and QWR aim to bridge the gap between traditional therapy and digital innovation, making high-quality mental health care more scalable and patient-centric. The AI-powered immersive VR therapy marks a significant step forward in integrating AI, neuroscience, and immersive technologies to revolutionize mental health care worldwide. #AI #VR #MentalHealthTech #DigitalTherapy #HealthcareInnovation #AIinHealthcare #VirtualReality #MedTech #ImmersiveTherapy #MentalHealthAwareness #HealthTech #CBT #VRTherapy #Neuroscience #FutureOfHealthcare #dseidehealthcarenetwork Source: India Med Today

A group of childhood friends from Hyderabad is set to disrupt the global glove manufacturing industry, challenging the dominance of Malaysia and China. With a vision to establish India as a key player in the medical and industrial glove sector, these entrepreneurs have launched a state-of-the-art facility that focuses on innovation, sustainability, and self-reliance. For decades, Malaysia and China have controlled a significant share of the global glove market, supplying hospitals, laboratories, and industries worldwide. However, the COVID-19 pandemic exposed the risks of supply chain dependence on a few countries. Recognizing this gap, the Hyderabad-based team has leveraged advanced automation, AI-driven quality control, and eco-friendly production techniques to manufacture high-quality gloves at competitive prices. Their venture aligns with India’s “Make in India” initiative, aiming to reduce import dependency and position India as a global supplier. By integrating cutting-edge technology and sustainable materials, the startup seeks to cater to growing demand while ensuring superior safety standards. With a commitment to excellence and a clear strategy, these childhood friends are on a mission to make India a formidable contender in the global glove industry, offering a reliable alternative to Malaysia and China’s long-standing monopoly. #MakeInIndia #GloveManufacturing #HealthcareInnovation #MedTech #StartupIndia #IndianManufacturing #SupplyChain #DigitalHealth #AIinHealthcare #SustainableManufacturing #HealthcareStartups #HyderabadStartups #MedicalGloves #IndustrialGloves #TechDriven #dseidehealthcarenetwork Source: Deccan Herald

Between February 10 and February 15, 2025, Indian startups experienced a significant surge in investments, collectively raising over $357 million across 21 deals. This influx of capital was predominantly driven by the fintech and artificial intelligence (AI) sectors, reflecting the growing confidence of investors in India's technological advancements and market potential. Fintech Sector Highlights The fintech landscape in India continues to attract substantial investments, underscoring the country's shift towards digital financial solutions. Notable among the recent funding rounds is the $1 million pre-seed investment secured by Rupeeflo, a fintech startup aiming to revolutionize financial services for underserved populations. Additionally, ArthAlpha, another emerging fintech company, raised $2 million in a seed round, focusing on providing innovative financial products tailored to the needs of small and medium-sized enterprises. These investments highlight the ongoing efforts to enhance financial inclusion and the delivery of tailored financial solutions in the Indian market. AI Sector Developments The artificial intelligence sector in India is witnessing rapid growth, with startups leveraging AI to address diverse challenges across industries. Lucidity, an AI-driven analytics firm, garnered $21 million in Series A funding. The company specializes in providing advanced data analytics solutions to enterprises, enabling them to make informed decisions and optimize operations. This investment signifies a strong belief in the potential of AI to transform traditional business processes and drive efficiency. Diverse Sector Investments Beyond fintech and AI, other sectors also attracted significant investments: Footwear Industry: JQR, a footwear startup, attracted $25 million, indicating investor confidence in the brand's potential to disrupt the traditional footwear market with innovative designs and sustainable practices. Wellness Sector: Bold Care, focusing on men's wellness products and services, received $5 million in Series A funding. This investment will aid the company in expanding its product line and reaching a broader audience, addressing a growing demand for specialized wellness solutions. Sports Industry: GoRally, a startup dedicated to promoting pickleball—a sport gaining popularity in urban areas—secured $750,000 in a pre-seed round. The funds are earmarked for establishing dedicated pickleball facilities and organizing events to foster community engagement. Government Initiatives and Market Outlook The Indian government's proactive stance on fostering innovation and entrepreneurship has created a conducive environment for startups. Initiatives such as the "IndiaAI Mission," with a budget allocation of $1.25 billion, aim to bolster AI infrastructure and public sector applications, further enhancing investor confidence in the country's tech ecosystem. The recent funding surge across various sectors not only underscores the robustness of India's startup ecosystem but also highlights the diverse opportunities that attract both domestic and international investors. As fintech and AI continue to lead the charge, other industries are also making significant strides, contributing to a dynamic and evolving market landscape. Source: Analyticsinsight #IndianStartups #StartupFunding #Fintech #AI #ArtificialIntelligence #TechInnovation #InvestmentNews #IndianEconomy #VentureCapital #StartupGrowth #Entrepreneurship #FundingNews #TechStartups #DigitalIndia #AIRevolution #dseidehealthcarenetwork

Towards improving emergency medical services in India, an AIIMS professor has praised Blinkit Ambulance, a new initiative set to transform healthcare delivery. Blinkit Ambulance leverages technology to ensure quick, efficient, and reliable emergency care, particularly for those living in underserved or remote areas. The service is designed to respond faster than traditional ambulances, bridging the gap between emergency situations and timely medical interventions. According to the AIIMS professor, Blinkit Ambulance represents a significant step forward in India’s healthcare revolution. The ambulance service uses an AI-powered system that optimizes response times by utilizing real-time traffic data, GPS, and predictive analytics. This allows Blinkit ambulances to avoid congested routes, ensuring faster access to critical care. Additionally, the ambulances are equipped with state-of-the-art medical equipment, offering life-saving support while en route to hospitals. The professor further emphasized that this initiative is a game-changer for India’s public health landscape. With the ability to reach even the most rural regions, Blinkit Ambulance can ensure that medical help is not delayed, potentially saving countless lives. By harnessing the power of artificial intelligence, Blinkit is not only improving emergency medical response but also setting a precedent for the future of healthcare in India. With the country facing significant healthcare challenges, innovations like Blinkit Ambulance offer a glimpse of a healthier future where technology plays a key role in delivering timely, life-saving care. source: business standard #HealthcareRevolution #BlinkitAmbulance #EmergencyCare #AIInHealthcare #HealthTech #AIForGood #MedicalInnovation #IndiaHealthcare #FasterResponse #SavingLives #TechnologyInMedicine #RuralHealthcare #HealthcareInnovation #SmartAmbulance #HealthcareTransformation #AIForEmergency #FutureOfHealthcare #MedicalTech #AIInIndia #HealthTechSolutions #TimelyCare #dseidehealthcarenetwork

A groundbreaking medical tech startup, Breath of Life, is making strides in neonatal care by developing an innovative cooling device aimed at healing newborns suffering from asphyxia. Asphyxia in newborns is a serious condition caused by a lack of oxygen during birth, potentially leading to brain damage or even death. Traditional methods of treatment have been limited, but Breath of Life is pioneering a new approach by using controlled therapeutic hypothermia. The cooling device works by lowering the body temperature of the newborn in a precise, controlled manner. This cooling process slows down the metabolic activity in the brain, offering critical protection against brain injury caused by lack of oxygen. Studies have shown that therapeutic hypothermia can significantly reduce the risk of severe neurological impairments when administered in the first hours after birth. What sets Breath of Life apart is its portable, easy-to-use design, which allows healthcare professionals in both well-resourced and low-resource settings to administer the treatment. The device is non-invasive, reducing the risk of complications that could arise from other methods. By providing timely and efficient intervention for newborns with asphyxia, Breath of Life aims to dramatically improve survival rates and quality of life for infants around the world. Their mission is to ensure that more babies have the chance to grow up healthy and strong, making a lasting impact on neonatal care globally. Source: YOURSTORY #BreathOfLife #NeonatalCare #NewbornHealth #AsphyxiaTreatment #TherapeuticHypothermia #InnovationInHealthcare #MedicalTechnology #NewbornCareRevolution #CoolingDevice #SavingLives #StartupsForGood #InfantCare #HealthTech #NeonatalInnovation #FutureOfHealthcare #BrainProtection #InfantSurvival #HealingNewborns #MedicalInnovation #TechForGood #HealthcareSolutions #dseidehealthcarenetwork

The BW Healthcare Excellence Awards & Summit 2025 is a distinguished event dedicated to honoring outstanding contributions in the healthcare sector. Scheduled for February 8, 2025, in New Delhi, this summit serves as a platform to recognize and celebrate the exceptional work of healthcare institutions and professionals across India. In recent years, India has witnessed significant advancements in healthcare, driven by both public and private sector initiatives aimed at strengthening the nation's healthcare infrastructure. The BW Healthcare Excellence Awards aim to honor institutions that have demonstrated resilience and adaptability, excelling in innovation, research and development, public health initiatives, sustainability, and efforts to make healthcare accessible to the masses. The awards ceremony is preceded by a day-long summit featuring discussions on the most recent and relevant healthcare topics. Esteemed speakers, including senior doctors and industry leaders, will share insights on advancements, challenges, and the future of healthcare in India. The summit provides a valuable opportunity for networking, knowledge exchange, and fostering collaborations among healthcare professionals, organizations, and experts. The BW Healthcare Excellence Awards & Summit 2025 not only acknowledges the achievements of healthcare institutions but also inspires continued innovation and leadership in the sector. By highlighting exemplary work and facilitating discussions on pressing healthcare issues, the event contributes to the ongoing development and improvement of healthcare services in India. Source: BW Healthcare #BWHealthcareExcellence2025 #HealthcareInnovation #MedicalLeadership #FutureOfHealthcare #HealthcareSummit #HealthcareAwards #HealthcareExcellence #HealthcareLeadership #HealthcareInnovation #HealthcareFuture

Johnson & Johnson has recently introduced the TECNIS PureSee intraocular lens (IOL) in India, aiming to enhance vision correction for individuals with presbyopia. This purely refractive IOL is designed to provide uninterrupted, high-quality vision with superior contrast and low-light performance, comparable to that of a monofocal IOL. The TECNIS PureSee IOL addresses common visual disturbances such as halos, glare, and starbursts, ensuring a clearer visual experience for patients. Its design also enhances surgical ease, offering high tolerance to refractive errors and ensuring precise visual outcomes. Cataract surgery is among the most frequently performed procedures globally, with approximately 28 million surgeries conducted annually. However, only 10-15% of patients currently receive advanced optical IOLs specifically designed to address conditions like astigmatism and presbyopia. The introduction of the TECNIS PureSee IOL in India provides surgeons and patients with a premium option that combines clarity of vision with reduced visual symptoms. This launch reflects Johnson & Johnson's commitment to advancing eye health and offering innovative solutions to meet the evolving needs of patients and healthcare professionals in India. Source: INDIAMED TODAY #JohnsonAndJohnson #IntraocularLens #TECNISPureSee #EyeCare #VisionCorrection #CataractSurgery #Presbyopia #MedicalTechnology #HealthcareInnovation #DigitalHealth #MedTech #Ophthalmology #EyeHealth #SurgicalAdvancements #HealthTech #dseidehealthcarenetwork

Lung cancer remains one of the leading causes of cancer-related deaths worldwide, primarily due to late diagnosis. However, artificial intelligence (AI) is revolutionizing lung cancer detection by enabling faster, more accurate, and early identification of malignant nodules in lung scans. AI-powered systems use deep learning and machine learning algorithms to analyze medical imaging, such as computed tomography (CT) scans, with remarkable precision. These AI models are trained on vast datasets, allowing them to detect abnormalities that might be missed by human radiologists. Studies have shown that AI-assisted diagnosis can improve detection rates, reduce false positives, and minimize the workload on healthcare professionals. One of the biggest advantages of AI in lung cancer detection is its ability to recognize patterns in imaging data much faster than traditional methods. AI can differentiate between benign and malignant nodules, helping doctors make more informed decisions. Additionally, AI can assist in risk assessment, predicting the likelihood of cancer progression based on a patient’s medical history and imaging results. Moreover, AI integration with cloud-based platforms allows real-time analysis and collaboration among specialists worldwide, ensuring faster diagnosis and treatment planning. AI-driven lung cancer detection tools also help in screening high-risk populations, such as smokers and individuals with a family history of lung cancer, improving early detection rates and survival outcomes. Despite these advancements, AI is not meant to replace radiologists but rather to enhance their efficiency and accuracy. As AI technology continues to evolve, it holds great promise for transforming lung cancer diagnosis, reducing mortality rates, and ultimately saving lives. By integrating AI into healthcare, we move one step closer to a future where lung cancer can be detected at its earliest stages, leading to timely and effective treatment. Source: The financial express #LungCancer #AIinHealthcare #EarlyDetection #CancerDiagnosis #MedicalAI #LungCancerAwareness #ArtificialIntelligence #HealthTech #AIforGood #Radiology #CancerResearch #CTScan #HealthcareInnovation #PrecisionMedicine #SaveLives #dseidehealthcarenetwork

New Delhi [India], February 12: India's future is being shaped by a new wave of innovative companies revolutionizing industries through technology, creativity, and purpose-driven leadership. From mental healthcare to digital marketing, sustainable fashion, luxury architecture, and finance education, these visionary businesses are setting new benchmarks for excellence. They are not only disrupting traditional markets but also redefining accessibility, sustainability, and consumer engagement. As 2025 unfolds, these companies are driving economic growth, empowering individuals, and bringing cutting-edge solutions to real-world challenges. Their groundbreaking work is a testament to India's entrepreneurial spirit and its position as a global leader in innovation and industry transformation. 1. Soulbol Healthtech Private Limited 2. G-TECH INFO INDIA PRIVATE LIMITED 3. ToonsFanatic 4. The Next Decor 5. ATELIER ASTIL BY Arpita Sharma 6. Apple's Height 7 Kautilya Academy 8. Finplan Edu 9. Nujay Pharma Industries 10. Exhibition Globe Source: Business Standard #IndiaInnovation #TechRevolution #StartupIndia #Entrepreneurs #FutureOfIndia #GameChangers #BusinessLeaders #IndustryDisruptors #EconomicGrowth #AI #HealthTech #DigitalMarketing #SustainableLiving #LuxuryDesign #EdTech #FinTech #MedTech #Branding #ECommerce #Manufacturing #GlobalLeadership #VisionaryStartups #IndianEntrepreneurs #SmartSolutions #GrowthMindset #dseidehealthcarenetwork

The Indian medical technology (medtech) industry has expressed significant disappointment following the Union Budget 2025, citing the government's failure to address critical sectoral demands. Despite the industry's anticipation for supportive measures, the budget did not introduce a dedicated fund for research and development (R&D) in medical technology, a longstanding request from industry associations. Rajiv Nath, Forum Coordinator of the Association of Indian Medical Device Industry (AiMeD), acknowledged the budget's positive macro-economic and policy directions aimed at strengthening the economy. However, he expressed disappointment over the absence of investment promotion measures for the medtech sector. Nath highlighted the industry's expectation for the government to address the sector's 70% import dependence, exacerbated by inadequate tariff protection with duties ranging from zero to 7.5% in most cases. He noted that the import bill is projected to exceed ₹75,000 crore this year. Pavan Choudary, Chairman of the Medical Technology Association of India (MTaI), lauded initiatives such as the establishment of daycare cancer centres and human resource development. However, he emphasized the industry's hope for reductions in customs duties on medical devices that are not substitutable in the near term. The medtech sector had also anticipated the introduction of a dedicated fund for R&D to foster innovation and reduce import dependence. The absence of such a fund in the budget has been a significant letdown for industry stakeholders. In summary, while the Union Budget 2025 includes measures aimed at economic growth and healthcare infrastructure development, it has notably overlooked the specific needs of the medtech industry. The lack of targeted support for reducing import dependence and promoting domestic manufacturing has left industry leaders concerned about the future competitiveness and self-reliance of India's medtech sector. Source: Insights Citeline #medtechstartup #medtechinindia #dseidehealthcarenetwork

The Future of Innovation Expo at Invest Karnataka 2025 is poised to be a landmark event, showcasing groundbreaking technologies that are set to redefine various industries. Supported by the Government of Karnataka and spearheaded by M.B. Patil, Minister for Large & Medium Industries and Infrastructure Development, the expo aims to serve as a premier platform for industry leaders, startups, and innovators to display advancements and foster global collaborations. Scheduled to be inaugurated by Rajnath Singh, Union Minister of Defence, the event will also feature a keynote address by Rahul Gandhi, Leader of the Opposition in the Lok Sabha. Dignitaries such as Governor Thaawar Chand Gehlot, Chief Minister Siddaramaiah, Deputy Chief Minister D.K. Shivakumar, and Minister M.B. Patil are expected to grace the occasion. The expo will highlight cutting-edge solutions across diverse sectors, including drone technology, space tech, agri-tech, health tech, semiconductors, electric mobility, and sustainable manufacturing. Attendees will witness autonomous solutions for manufacturing, aerospace, and defense, reinforcing Karnataka’s status as India’s innovation powerhouse. The event will bring together global industry leaders, high-growth startups, and research-driven enterprises, providing a dynamic networking space for investors, policymakers, and tech pioneers. Prominent exhibitors such as GE Healthcare, Hero Future Energies, River Mobility, Sarla Aviation, GalaxEye Space, and LAM Research will showcase next-generation innovations poised to redefine industries. The Karnataka Pavilion will spotlight the state’s thriving startup ecosystem, featuring homegrown ventures like Flying Wedge, Bellatrix, Skyserve, and Flux Auto, further cementing Karnataka’s leadership in technology and research-driven enterprise development. With a strong focus on cross-sector collaborations, investments, and knowledge-sharing, the expo will offer insights into sustainability, industrial transformation, emerging business models, and future-ready technologies. As Karnataka continues to position itself as a global hub for investment and technology-driven industries, the Future of Innovation Expo at Invest Karnataka 2025 is a must-visit platform for businesses and investors looking to engage with cutting-edge innovations and forge strategic partnerships. Source: Manufacturing today #FutureOfInnovationExpo #InvestKarnataka2025 #TechInnovation #BreakthroughTech #StartupEcosystem #NextGenTechnology #SmartManufacturing #Drones #AI #SpaceTech #SustainableTech #ElectricMobility #DeepTech #IndustrialRevolution #TechCollaboration #GlobalInnovation #dseidehealthcarenetwork

As India navigates the ever-evolving landscape of healthcare, one area of transformation stands out: the rise of e-pharmacies. E-pharmacies have become an essential part of the healthcare delivery system, especially highlighted during the COVID-19 pandemic. With the sector growing rapidly, Anant Kharad, Director at TH Healthcare and Life Sciences (a specialist healthcare division of TH Global Capital, formerly known as Technology Holdings), shares his insights during a panel discussion at the VCCircle Healthcare Summit 2025 on the growth and future of e-pharmacies in India. The pandemic served as a catalyst for the e-pharmacy sector. According to Kharad, while India is known for adopting technology at a rapid pace, COVID-19 made the country realize the need for a more accessible, affordable, and authentic way to obtain medicines. E-pharmacies filled that gap, offering convenience for customers across different demographics— from senior citizens ordering their medications online to young professionals seeking time-saving solutions for themselves and their families. Kharad emphasized three key pillars that e-pharmacies have successfully addressed: accessibility, affordability, and authenticity. E-pharmacies have transformed accessibility by bringing medications to the doorstep, regardless of the customer's location or time constraints. The sector has also enhanced affordability by eliminating traditional markups, providing better pricing to consumers. In terms of authenticity, e-pharmacies have taken steps to ensure that the medicines they provide are legitimate, reducing the risk of counterfeit drugs in the market. Source: VCCircle #healthcarestartup #gealthcarefunding #dseidehealthcarenetwork

Apollo Hospitals Enterprise Ltd., a leading healthcare provider in India, has reported a significant increase in its financial performance for the third quarter ending December 31, 2024. The company's consolidated net profit surged by 51.8% year-on-year, reaching ₹3.72 billion (approximately $42.5 million), surpassing analysts' expectations of ₹3.51 billion. This impressive growth is primarily attributed to higher occupancy rates across Apollo's network of hospitals. The overall occupancy rate rose to 68% from 66% in the same period the previous year, driven by a substantial increase in patient inflows. Additionally, there was a notable rise in surgery volumes, further contributing to the company's robust performance. The healthcare services segment, which accounts for more than half of Apollo's total revenue, experienced a 12.9% increase, propelling the overall revenue up by 14% to ₹55.27 billion. This figure slightly exceeded analysts' projections of ₹55.23 billion. Apollo's digital health and pharmacy vertical, encompassing the Apollo 24/7 platform, also demonstrated strong performance with a 14.8% year-on-year revenue growth. This segment offers online consultations and pharmacy services, reflecting the company's successful integration of digital solutions to meet evolving patient needs. Looking ahead, Apollo Hospitals is on track to expand its capacity by adding 3,512 new beds over the next three to four years, starting from the fiscal year 2026. This strategic expansion aims to meet the growing demand for healthcare services across India. In terms of regional performance, the Andhra Pradesh and Telangana region led with a 24% revenue growth, a 15% increase in inpatient volume, and a 9% rise in Average Revenue Per Occupied Bed (ARPOB) to ₹63,013. Occupancy in this region also saw a significant jump to 66%. The Karnataka region reported a 17% revenue growth with a 71% occupancy rate, while the Eastern region's revenue increased by 8% with stable occupancy levels. The company's board has declared an interim dividend of ₹9 per share, with February 15 set as the record date. The dividend is scheduled to be paid by February 28. Apollo Hospitals' strong financial results underscore its commitment to providing quality healthcare services and its strategic focus on expanding capacity to meet increasing patient demand. The company's integrated approach, combining traditional healthcare services with digital innovations, positions it well for sustained growth in the evolving healthcare landscape. Source: marketscreener #ApolloHospitals #HealthcareGrowth #HospitalIndustry #HealthcareDemand #MedicalExcellence #IndiaHealthcare #PatientCare #HealthcareInnovation #DigitalHealth #HealthcareExpansion #MedicalServices #HealthcareNews #HealthcareMarket #Apollo24x7 #HospitalRevenue #MedicalTechnology #HealthTech #HealthcareInvestment #QualityHealthcare #HealthcareUpdates #dseidehealthcarenetwork